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ABSTRACT 
 Epstein-Barr virus (EBV) in a human herpesvirus. It infects about 90% of 
the human population, and is the main causative agent of infectious 
mononucleosis. The incubation period, the time between viral acquisition and 
onset of symptoms, is unusually long in patients presenting with infectious 
mononucleosis, lasting about six weeks. In addition to causing acute illness, 
there can also be long-term consequences as the result of acquisition of the virus, 
including nasopharyngeal carcinoma and lymphoma. Nevertheless, there 
remains a surprising dearth of knowledge regarding the establishment of and 
immune response to persistent EBV infection in its natural hosts, especially 
during the incubation period.  
We sought to address many of these gaps by studying the incubation 
period, acute phase, and convalescence of undergraduates experiencing 
infectious mononucleosis during primary natural EBV infection in a cohort of 
prospectively studied volunteers. Particular attention was paid to the previously 
uncharacterized incubation period. Our findings have focused on understanding 
the immune response that occurs in young adults presenting with infectious 
mononucleosis, via gene expression changes as observed in peripheral blood 
mononuclear cells and innate and adaptive immune cells. 
 Using a systems biology approach we discovered that important gene 
expression changes occur during the immune response to primary EBV infection. 
A typical antiviral type I interferon response was not observed at onset of 
infectious mononucleosis symptoms, but rather up to two weeks prior. The gene 
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expression signature at symptom onset was dominated by cell cycle related 
genes, probably due to the CD8 T cell lymphocytosis, and type II interferon 
regulated genes. Interestingly, comparison of the EBV signature with other acute 
viral infections revealed very little similarity. The EBV signature showed the 
greatest similarity with hemophagocytic syndromes. This result is consistent with 
the view that infectious mononucleosis is an immunopathologic disease, and is 
supported by evidence that EBV can cause hemophagocytic lymphohistiocytosis.  
 As an extension of this work, we carefully examined changes in cellular 
phenotypes and population frequencies to determine if there were significant 
alterations to certain compartments during the response to primary EBV infection. 
We observed a type I interferon signature in a larger subset of study participants 
during the incubation period. This response was concurrent with the transition of 
virally infected B cells from the oral cavity to the blood, a decline in plasmacytoid 
dendritic cells from the circulation, and a polyclonal CD8 T cell activation. No 
EBV specific CD8 T cells activation was observed until the onset of infectious 
mononucleosis symptoms. 
A major obstacle to understanding EBV related sequelae has been the 
lack of an efficient animal model for EBV infection, although progress in primate 
and mouse models has recently been made. Taken together, the data compiled 
in this thesis provide important first descriptions of the immune responses that 
occur during the establishment of a natural persistent infection in humans. Key 
future challenges are to develop protective vaccines and effective treatment 
regimens. 
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INTRODUCTION 
 Epstein-Barr virus (EBV) is a highly ubiquitous human pathogen, infecting 
up to 90% of the human population by the age of 35. Infection with EBV is more 
common in less developed nations, and evidence is emerging that the 
seroprevalence is declining among wealthier countries (1, 2). Summarized here 
is our current understanding of how EBV is transmitted and replicates, the 
prevalent immune responses that control initial infection, and steps toward the 
treatment and prevention of EBV related diseases. 
 
Epstein-Barr Virus  
 EBV is a member of the herpesviridae family of DNA viruses, which all 
cause lifelong infection in their hosts. Generally, herpesviruses are species 
specific, with each virus usually only naturally infecting one species of host and 
are limited to mammals, bird and reptiles. Of the over 200 discovered members, 
only nine of these infect humans (3). These viruses are classified on the basis of 
similarities in morphological and genetic criteria. Morphologically, herpesviruses 
hold a number of features in common: (i) a linear double-stranded DNA core, 
varying in length between 124-295 kb; (ii) an icosohedral capsid made up of 162 
capsomeres; (iii) a poorly defined tegument surrounded by a lipid envelope with 
viral glycoproteins (4).  
The human herpesviruses can be divided into three different subfamiles: 
alpha, beta and gamma herpesviruses. These subfamilies form latent infections 
in distinct cell types, neurons, lymphocytes, and B cells, respectively (3). Alpha 
herpesviruses include herpes simplex virus (HSV) 1, HSV 2, and varicella zoster 
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virus (VZV). Beta herpesviruess include cytomegalovirus (CMV), and human 
herpesviruses 6A, 6B, and 7. Gamma herpesviruses include EBV and Kaposi’s 
sarcoma virus. While alpha herpesviruses can sometimes infect a wider range of 
hosts, both the beta and gamma herpesviruses are limited to the order of the 
natural host for the virus in question (3). Of these viruses, human herpesvirus-6 
is estimated to be the most prevalent, with more than 90% of the population 
infected. The least common is Kaposi’s sarcoma virus, with as little as 2% of the 
population infected (5). 
 Two distinct genera, rhadinovirus (RDV) and lymphocryptovirus (LCV), 
comprise the human gamma herpesvirus subdivision. Across species they show 
a high degree of genomic structural similarity, with the exception of a small 
subset of nuclear proteins (6, 7). Epstein-Barr virus is a member of the LCV 
genus, specifically an Old World LCV (8). Several species of primates are 
naturally infected with LCVs that have high colinearity with the human tropic EBV 
(3). It is important to note that LCVs exclusively infect primates. The mouse virus 
murid herpesvirus-68 (MHV-68), which is commonly used to model EBV infection 
is actually an RDV (9), and thus is not an ideal pathogen for recapitulating the 
response to EBV. 
Across populations, there are two types of EBV. The main differences 
between these types EBV infected individuals in the Western world tend more 
often to be infected by type 1 EBV than type 2 EBV (3, 10). Whether or not 
superinfection with both strains is possible in immunocompetent individuals 
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remains unknown, although both strains are readily detectable in the oral cavity 
of patients with human immunodeficiency virus (11, 12). 
 
Routes of Transmission 
Kissing is the major route of transmission of primary EBV infection among 
adolescents and young adults. This was elegantly documented by Hoagland's 
careful clinical observations (13) and confirmed many decades later by a 
prospective study at the University of Minnesota (14). Penetrative sexual 
intercourse has been postulated to enhance transmission (15), but we have 
found that subjects reporting deep kissing with or without coitus had the same 
risk of primary EBV infection throughout their undergraduate years (14).  
 The incubation period of infectious mononucleosis is approximately 6 
weeks. Hoagland's clinical records suggested an incubation period of 32-49 days 
based on the dates of kissing episodes until the onset of infectious 
mononucleosis (13). A well-documented case was reported by Svedmyr et al. 
(1984) in which the kissing event occurred 38 days prior to onset of symptoms 
(16). Behavioral data from our medical history questionnaires collected during 
prospective studies are consistent with an incubation period of 42 days (Balfour 
et al. unpublished observations). 
 Besides deep kissing, primary EBV infection can also be transmitted by 
blood transfusion (17), solid organ transplantation (18), or hematopoietic cell 
transplantation (19), but these routes account for relatively few cases overall. 
Alfieri et al. (1996) used polymorphisms in the EBV BAMHI-K fragment length 
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and size polymorphisms in EBV nuclear antigen (EBNA) -1, -2 and -3 proteins to 
identify the specific blood donor responsible for transmitting EBV to a 16-year-old 
liver transplant recipient who subsequently developed infectious mononucleosis. 
 The way young children contract EBV is unknown. A reasonable 
supposition is that they are infected by their parents or siblings who are "carriers" 
of the virus and who intermittently shed it in their oral secretions (20). An extreme 
example of this is the very early acquisition of EBV among three distinct 
Melanesian populations whose infants have multiple caregivers that premasticate 
the babies’ food (21) 
 
Incubation period of EBV 
The long incubation period of EBV continues to be poorly understood due 
to a lack of samples obtained between the time of infection and presentation with 
EBV related symptoms. During primary infection, viral replication is first detected 
in the oral cavity (14). The virus can infect tonsillar epithelial cells as well as B 
cells in the parenchyma of the tonsil (22). There may be a cyclic nature to the 
pattern of infection in the oral cavity as it has been shown in vitro that virus 
derived from epithelial cells has a much higher entry efficiency for infecting B 
cells and vice versa, resulting in a switched viral tropism depending on the cell 
type in which the virus replicates (23), discussed in detail below. 
During the incubation period, the virus moves from the oral cavity to the 
blood. Previously, little was known about the kinetics or means of this transition, 
but this interesting period has been more carefully elucidated by the work 
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described in this thesis. Early infection in the oropharynx is shown in Figure 1-1. 
A type I interferon response was detected by gene expression profiling of 
peripheral blood approximately 2 weeks prior to symptom onset in some subjects 
experiencing primary EBV infection. Viral genomes can sometimes be detected 
in the peripheral blood as early as three weeks prior to symptom onset and 
consistently at least one week prior to illness (24), where it is probably 
maintained latently in resting memory phenotype B cells (25).  
 
 
 
 
 
7 
 
Figure 1-1. Establishment of initial EBV infection in the oropharynx and 
blood. Epithelial cell derived EBV is transmitted to an EBV naïve host via 
infected saliva. Viral particles infect susceptible B cells, resulting in transformed 
LatencyIII cells. These cells replicate, creating a reservoir of virus. Some pass 
through the germinal center reaction, with the latent membrane proteins 
augmenting B cell receptor signaling. These Latency0 cells become memory-like, 
changing their trafficking patterns and recirculate between the periphery and 
oropharynx. Other LatencyIII cells undergo reactivation, producing virus which 
infects epithelial cells. Virus is then shed into the oral cavity. 
 
Replication and Tropism 
 After an inoculum of saliva containing viable EBV enters the oral cavity of 
an EBV naïve host, the virus may infect either oral epithelial cells or B cells in the 
lymphatic tissue of Waldeyer’s ring. While it is uncertain which of these events is 
more likely to occur first, attachment of EBV to B cells is effected by binding of 
Oral cavity Tonsil Epithelium 
Epithelium 
derived EBV 
B cell 
Transformed 
Latency III 
Blood 
LIII 
LIII 
LII 
L0 
Lytic 
Reactivation 
GC  
8 
the EBV glycoprotein gp350/220 to the C3d complement receptor CD21 on B 
cells (26). Fusion and entry of the virus is then mediated by another EBV 
glycoprotein, gp42, which binds to the MHC class II molecule HLA-DR on the B 
cell to trigger endocytosis of the virus (27). Attachment to epithelial cells 
proceeds slightly differently. The EBV open reading frame BRMF2 encodes a 
protein that has binding affinity to a number of α integrins known to be present on 
surface of squamous epithelial cells (28, 29). In either case final fusion of EBV 
with the endocytotic membrane or plasma membrane, respectively, is mediated 
by gH/gL and gB (27). Virus may be replicated in either epithelial cells or B cells 
during persistent infection, although entry into epithelial cells is always 
significantly (logs) less efficient (23). Virus shed into saliva has been found to be 
primarily derived from epithelial cells due to the presence of gp42 and lack of 
HLA-DR present on the envelopes of EBV in saliva. These envelope protein 
differences obtained during budding explain the switch tropism observed in EBV 
entry patterns (30). 
Once the viral genome has been transported to the nucleus, virally 
encoded DNA polymerases replicate the linear viral DNA. During the lytic phase 
of infection, there are three major phases of gene expression known as the 
immediate early, early, and late. Two key genes are expressed at the immediate 
early phase, BZLF1 and BRLF1. These genes encode the proteins ZEBRA and 
Rta, which are activators that initiate the transition from latency to lytic infection 
(31-33). Early phase genes generally consist of proteins important for the 
replication of the viral genome such as DNA polymerases, mRNA transport 
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enhancers, and factors for immune evasion. The late phase genes are largely 
structural proteins for packaging of the virus (3).  
Latency is an important stage of the EBV life cycle, wherein latency is 
maintenance of viral infection without active lytic replication. Lytic replication is 
not the only mechanism that drives replication of the EBV genome. EBV genetic 
material may also be replicated during the various stages of latency through 
normal host DNA replication machinery. During latency, the EBV genome 
circularizes in the nucleus and is tethered to host chromosomes by the EBV 
nuclear antigen (EBNA)-1 protein (34). This episome contains an origin that is 
readily bound by host DNA polymerases in an EBNA-1 dependent fashion. 
EBNA-1 then assists in segregation of the replicated EBV genome to daughter 
cells following B cell division (3). This type of replication is considered “vertical” 
replication. 
A number of latency stages exist for EBV infected B cells, some of which 
are considered only “partial” latencies as some EBV encoded genes are still 
expressed. Each type of latency has a distinct gene expression pattern. Latency 
III is the state of transformed lymphoblastoid B cells, and results in activation of a 
proliferation program in these cells. Six EBV nuclear antigen proteins, two latent 
membrane proteins (LMP), and EBV-encoded small RNAs (EBERs) are encoded 
during Latency III (4). In both Latency II and Latency I EBNA1 is expressed, and 
LMP1 and LMP2 are expressed in Latency II only. These phases are seen 
transiently or not at all during the progress of normal EBV infection in the healthy 
host (35). Latency II is typically observed in EBV related cancers or in germinal 
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center reactions which may be the transition of EBV infected B cells from Latency 
III to Latency 0 (36). “True” latency is only achieved at Latency 0, in resting 
memory-like B cells. No EBV encoded proteins are expressed in this phase of 
latency, and the EBV episome remains silent in the host nucleus (37). Cells in 
Latency 0 recirculate from the blood to the oropharynx, and comprise virtually all 
cells that can be detected in peripheral blood at both acute and latent stages of 
EBV infection (38). Only about one in a million circulating B cells is infected with 
EBV in healthy EBV infected adults (39). A complete cycle of EBV infection from 
acquisition to shedding may be seen in Figure 1-1. 
The reactivation of EBV from latent to lytic infection in vivo is presumably 
important for viral transmission and for EBV related pathologies, but the triggers 
for reactivation remain ill-defined. Extrapolating from data obtained in vitro, it has 
been hypothesized that stimulation of the B cell receptor of infected cells may act 
as a trigger, or that certain types of other maturation signals may act as triggers 
(3).  
 
Acquisition and Epidemiology  
EBV infection is extremely common worldwide and approximately 90% of 
adults become antibody-positive before the age of 30 (40-42). A recent example 
is that 1037 (90%) of 1148 subjects 18 and 19 years old participating in the U.S. 
National Health and Nutrition Examination Surveys (NHANES) between 2003 
and 2010 had IgG antibodies against EBV viral capsid (VCA) antigen, indicative 
of prior infection (1). 
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The prevalence of EBV antibodies in preadolescent children is lower, 
varying from 20% to 80% depending on age and geographic location. Factors 
clearly related to early acquisition of primary EBV infection include geographic 
region (reviewed in (43)), and race/ethnicity (1, 44). Other factors implicated are 
socioeconomic status (45-47), crowding or sharing a bedroom (45, 48), maternal 
education (49), day care attendance (47), and school catchment area (45). 
 Regarding race/ethnicity, it was recently shown that antibody prevalence 
across all age groups of U.S. children 6 to 19 years old enrolled in NHANES 
between 2003 and 2010 was substantially higher in non-Hispanic blacks and 
Mexican Americans than non-Hispanic whites (1). The greatest disparity in 
antibody prevalence was among the younger children, especially the 6- to 8-
year-olds. Interestingly, the difference in antibody prevalence between whites 
and non-whites diminished during the teenage years. These NHANEs findings 
were confirmed (44) and extended to include younger children (18 months to 6 
years of age) living in the Minneapolis-St. Paul metropolitan area. The Twin 
Cities study showed that the divergence in age-specific antibody prevalence 
between blacks and whites was clearly apparent by the age of 5 years.  
Thus, family environment and/or social practices may differ among white 
and non-white families, which could account for this disparity in antibody 
prevalence in younger children. Alternatively, the explanation may be more 
closely linked to genetic differences between ethnicities, which is supported by 
the high frequency of concordance in same sex twins as opposed to non-twin 
siblings (50). Some 
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of virus. Non-white adults had significantly higher levels of EBV in oral wash 
samples than did white adults in a survey of parents with young children 
(Cederberg, et al., unpublished observations). This may or may not affect 
transmission among family groups. Within each race/ethnicity group, older age, 
lack of health insurance, and lower household education and income were 
statistically significantly associated with higher antibody prevalence.  
 Infectious mononucleosis occurs largely when EBV is first acquired after 
puberty. The age at which primary EBV infection is acquired may be increasing in 
developed countries (1, 51, 52). This is important to monitor because there is a 
complex interplay between age of acquisition, symptomatic versus asymptomatic 
primary infection, and the subsequent risk of EBV-associated cancers or 
autoimmune diseases. For example, younger age at the time of primary EBV 
infection among Kenyan infants was associated with elevated levels of EBV 
viremia throughout infancy, leading the investigators to postulate that these 
infants were at higher risk for endemic Burkitt lymphoma (53, 54). Another study 
found that Greenland Eskimo children acquired primary EBV infection at an 
earlier age and had higher titers of IgG antibody against VCA than did age-
matched Danish children (55). The authors speculated that early infection with "a 
large inoculum of EBV" explained why Eskimos were at high risk for 
nasopharyngeal carcinoma versus Danes who were not. Nevertheless, late 
acquisition of primary EBV infection is also detrimental in several contexts. 
Adolescents and young adults are more likely to experience infectious 
mononucleosis during primary infection than children (56). Furthermore, multiple 
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sclerosis (MS) is an inflammatory autoimmune disease that may be linked to 
EBV infection and risk of MS is higher amongst individuals who have 
experienced infectious mononucleosis (57). Infectious mononucleosis also 
increases the risk of Hodgkin’s lymphoma (58). Thus, since age of primary EBV 
infection is an important factor in infectious mononucleosis, it is an important 
consideration for EBV related diseases. 
 
Infectious Mononucleosis 
Of the diseases caused by EBV, infectious mononucleosis is the most well 
known. Infectious mononucleosis was the name coined by Sprunt and Evans 
(59) to describe a syndrome that resembled an acute infectious disease 
accompanied by atypical large peripheral blood lymphocytes. These atypical 
lymphocytes, also known as Downey cells (60), are actually activated CD8 T 
lymphocytes, most of which are responding to EBV-infected cells. EBV is 
medically important because of the severity and duration of possible acute illness 
and also because of its association with long-term consequences especially the 
development of certain cancers and autoimmune disorders (57, 61). From a 
basic biology standpoint, infectious mononucleosis also represents a natural 
example of initiation of a persistent viral infection.  
Our prospective studies have determined that 75% of young adults 
between the ages of 18 and 22 develop typical infectious mononucleosis after 
primary EBV infection. Approximately 15% have atypical symptoms and 10% are 
completely asymptomatic (14; Balfour et al. unpublished observations). There are 
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two common presentations among symptomatic patients. The first is the abrupt 
onset of sore throat, which many patients say is the worst sore throat they have 
ever had. Patients may also notice a swollen neck that results from cervical 
lymph node enlargement. Parenthetically, anterior and posterior cervical nodes 
are usually equally enlarged. The second most common presentation is the 
gradual onset of malaise, myalgia ("body aches") and fatigue. Table 1-1 shows 
the frequency of signs and their median duration in 72 undergraduate students 
studied prospectively. Most signs/symptoms have a median duration of 10 days  
but fatigue and cervical lymphadenopathy persist for a median of 3 weeks. Other 
findings, seen in fewer than 20% of cases in our experience, include abdominal 
pain, hepatomegaly, splenomegaly, nausea, vomiting, palatal petechiae, 
periorbital and eyelid edema, and rash. Rash is seen more often in patients given 
penicillin derivatives, which is most likely due to transient penicillin 
hypersensitivity (62). 
 
Table 1-1. Clinical features of primary EBV infections in 72 undergraduate 
students studied prospectively (48 women, 24 men; age range, 18-22 years). 
 
 
Feature No. of Subjects (%) Median Duration (Days) 
Sore Throat 68 (94%) 10 
Cervical 
Lymphadenopathy 58 (81%) 21 
Fatigue 52 (72%) 20 
Upper Respiratory 
Symptoms 46 (64%) 4.5 
Headache 38 (53%) 9.5 
Decreased Appetite 38 (53%) 9.5 
Feels Feverish 34 (47%) 4 
Myalgia (Body Aches) 33 (46%) 3 
15 
 Subclinical hepatitis documented by elevated levels of alanine 
aminotransferase occurs in approximately 75% of prospectively followed patients 
and, in some cases (5-10%), overt hepatitis develops with tender hepatomegaly 
and jaundice (Balfour et al. Unpublished observations).  
Primary EBV infection in preadolescents has not been thoroughly 
investigated most likely because prospective studies in young children are 
logistically difficult to conduct. The assumption has been that the majority of 
primary EBV infections in children before puberty are asymptomatic but it is 
possible that symptoms are generally milder in children and thus overlooked 
clinically. Young children, especially those under the age of 4 years, may not 
develop a positive heterophile antibody response during primary EBV infection 
(63) and unless specific EBV assays are performed, the diagnosis will be missed.  
It was previously thought that only 25%-50% of primary EBV infections in 
young adults result in symptomatic infection based on results from smaller 
prospective studies (15, 64-66). While our cohorts suggest that frequency is 
actually much higher, determining what factors differentiate symptomatic and 
asymptomatic seroconversion remains of great interest. Indeed, it has long been 
hypothesized that the magnitude of the CD8 T cell response may be the 
underlying cause of disease, specifically IFNγ produced by these cells which 
results in immunopathology. Heterologous immunity has been proposed as a 
potential mechanism of this phenomenon. Under this theory, memory cells 
primed by challenge with pathogens unrelated to EBV may be cross-reactive with 
EBV derived epitopes, thus enhancing the immune response to primary EBV 
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infection (67). Heterologous immunity may explain why infectious mononucleosis 
is more prevalent among adolescents than children (15). Cells specific for other 
common human viruses, however, only make up a small proportion of CD8 T 
cells expanded during infectious mononucleosis (68).  
Likewise, viral load has also been hypothesized to affect both 
lymphocytosis and symptoms in both adolescents and children. Previous studies 
examining primary EBV infection in children have revealed that seroconversion 
often occurs with comparatively little CD8 T cell expansion (69, 70). Recent 
evidence from a cohort of Gambian infants showed that children may exhibit high 
viral loads consistent with those observed during infectious mononucleosis, but 
lack the typical CD8 T cell overexpansion, and are asymptomatic. While there 
was no lymphocytosis, a substantial EBV specific CD8 T cell response could be 
detected nonetheless, making up a surprising 16% of circulating CD8s (71). This 
finding suggests that disease progression related to acquisition of primary EBV 
infection is caused by an immunopathologic CD8 T cell response rather than 
direct virologic damage, although further study of this is warranted. 
 
Complications of Acute Infectious Mononucleosis 
Fortunately, serious complications during the acute phase of primary EBV 
infection are rare. Table 1-2 shows reported complications divided into those 
estimated to occur in at least 1% of patients and those that are seen in fewer 
than 1% of cases (72-76). Splenic rupture is the most feared complication, which 
has kept many athletes out of competition for weeks. Current consensus is that 
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athletes may return to contact sports 3 weeks after onset of infectious 
mononucleosis provided they are afebrile, their energy has returned to normal, 
and they have no other abnormalities associated with primary EBV infection (77). 
 
 
Table 1-2.  Complications during acute primary EBV infection. 
 
Although most symptoms associated with infectious mononucleosis 
resolve in a matter of months, there can be severe and lasting disease that 
develops following primary EBV infection. One of these complications may 
manifest in the form of chronic active EBV (CAEBV). Patients presenting with 
CAEBV generally exhibit signs that can occur during infectious mononucleosis 
such as fever, lymphadenopathy, splenomegaly and hepatitis, and show 
Frequency of 
Complications 
Complication 
 
≥1% 
Airway obstruction due to oropharyngeal 
inflammation 
Meningoencephalitis 
Hemolytic anemia 
Streptococcal pharyngitis 
Thrombocytopenia 
 
 
 
 
<1% 
Conjunctivitis 
Hemophagocytic syndrome 
Myocarditis 
Neurologic disorders (other than 
meningoencephalitis 
Neutropenia 
Pancreatitis 
Parotitis 
Pericarditis 
Pnemonitis 
Psychological disorders 
Splenic rupture 
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markedly elevated levels of EBV DNA in the blood (78). Less frequently, patients 
may also present with lymphoma or hemophagocytic disease, a complication of 
EBV that is discussed in greater detail below (79). Interestingly, in many cases of 
CAEBV outside of the United States, particularly in Japan, EBV is reported to 
infect T or NK cells rather than its usual reservoir of B cells (78, 80). Several 
instances of B cell tropic CAEBV have also been reported, but these account for 
the minority of documented incidences (79, 81). While some patients have T or 
NK cell dysfunction, none of the subjects in a National Institutes of Health (NIH) 
study had mutations typically associated with EBV related immunodeficiencies 
and thus the disease observed in that study was considered to be largely 
idiopathic. The most successful treatment for CAEBV has been hematopoietic 
stem cell transplant. In the same NIH study, all but one of the patients who 
presented with CAEBV died within an average of six years unless a transplant 
was received. Those that survived all subsequently became negative for EBV 
DNA in the blood (82). 
EBV may also cause hemophagocytic disease, which is alternately 
referred to in the literature as EBV-associated hemophagocytic syndrome or 
EBV-associated hemophagocytic lymphohistiocytosis (HLH). The relative rarity of 
any form of HLH stands as a barrier to diagnosis, and thus cases of EBV-HLH 
are even more uncommon. The disease is characterized by fever, splenomegaly 
and hematologic cytopenias, though the key laboratory signs are high levels of 
ferritin and soluble CD25 (83, 84). The distribution of EBV-HLH seems to be 
similar to CAEBV, focused mainly in Asian populations and infecting T or NK 
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cells in those groups (85) though B cells are also infected in other populations 
(86). EBV-HLH may be related to one of several primary immunodeficiencies 
discussed below, but EBV infection may be a triggering event even in the 
absence of an identified genetic condition. Interestingly, my thesis research 
showed that the peripheral blood gene expression signature observed during 
infectious mononucleosis highly resembles that of HLH (87). This reinforces links 
between primary EBV infection as a trigger in the initiation of HLH. 
 
Diagnosis 
Infectious mononucleosis due to EBV should be suspected in patients, 
especially teenagers and young adults, who present with an acute illness 
characterized by sore throat, cervical lymphadenopathy, fever and fatigue. 
Clinical signs that make the diagnosis more likely are exudative pharyngitis with 
swelling of the uvula and tonsils; periorbital and eyelid edema; and symmetrical 
cervical and postauricular lymphadenopathy. 
 A “heterophile test” using one of a number of commercially available 
antibody kits is most often done to support the clinical diagnosis (Table 1-3). 
Heterophile tests are relatively inexpensive and easy to perform. However, 
heterophile antibodies by definition are not specific. They are IgM class 
antibodies directed against mammalian erythrocytes. False positive heterophile 
tests have been reported in myriad conditions including other acute infections, 
autoimmune disease, and cancer (88-92). Although heterophile tests are most 
commonly used to diagnose infectious mononucleosis, the U.S. Centers for 
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Disease Control and Prevention has recently advised against them "for general 
use" because of their non-specificity and the possibility of false negative results 
especially in young children (93). In our experience, however, if the clinical 
picture is typical of infectious mononucleosis and the heterophile antibody test is 
positive, no additional diagnostic procedures are necessary. 
 
a 0 to 3 weeks after onset of illness 
b 3 weeks to 3 months after onset of illness 
c 3 to 6 months after onset of illness 
d > 6 months after onset of illness 
 
Table 1-3. Staging EBV Infection by enzyme immunoassay patterns. 
 
 
 No single antibody test is perfect for confirming the diagnosis of primary 
EBV infection. Most patients (75%) will have VCA IgM antibodies at the onset of 
clinical illness and 95% eventually make them (Table 1-3). In prospective studies 
of EBV-naïve college students, we detected VCA IgM by EIA as early as 8 days 
before onset of symptoms. The median first day of detection was 2 days after 
onset of illness (Figure 1-2). However, a problem with IgM class antibody tests in 
general is cross-reactivity with related pathogens. In the case of VCA IgM 
antibodies, false positive results have been reported especially with 
cytomegalovirus infections (94).  
 
Stage of Infection VCA IgM VCA IgG EBNA-1 IgG 
Naïve Negative Negative Negative 
Acute Primarya 1—2+ Neg—1+ Negative 
Subacuteb 3—4+ 2—4+ Negative—1+ 
Convalescentc Negative—3+ 3—4+ Negative—2+ 
Pastd (90—95% of cases) Negative 3+ 3—4+ 
Pastd (5—10% of cases) Negative 3+ Negative 
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Figure 1-2. Kinetics of EBV viral load and antibody responses in subjects 
with primary EBV infection. Depicted are viral loads in whole blood, saliva, and 
oral cell pellets (black lines) as well as IgM and IgG antibodies to VCA and IgG to 
EBNA1 (colored lines). Note: the limit of detection of the EBV viral genomes in 
blood was 200 copies per mL of whole blood. 
 
 Depending on the assay platform and antigen used in the assay, VCA IgG 
antibodies are first detected during the first month of illness. IgG class antibody 
against the p18 component of VCA develops later than does IgG against the p23 
component (see Figure 1-3). Using an EIA with p18 as the antigen, we found in 
prospective studies that the median first day of detection after onset of illness 
was 31 with a very wide range of 1—118 days. Nearly everyone who 
experiences a primary EBV infection develops IgG antibodies to VCA (14), so 
this is the best single test to verify a previous EBV infection. It is superior to 
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EBNA-1 antibody tests because antibodies to EBNA-1 are slow to develop and 
5—10% of patients never make a response. Trends in viral load and antibody 
titer are shown in figures 1-2 and 1-3. 
 
Figure 1-3. Kinetics of antibody responses to additional EBV antigens as 
determined by immunoblot. Depicted are viral loads in whole blood, saliva, and 
oral cell pellets (black lines) as well as the relative kinetics of antibodies 
generated against the EBV antigens p18, p23, BZLF1, p138, and p54 (colored 
lines). The gene name of each antigen and the stage of expression (IE: 
immediate early, E: early, or L: late) are indicated in parentheses. 
 
 Antibodies against EBNA-1 are slow to appear with a median first day of 
detection of 91 days (Figure 1-2). Because of this, the presence of EBNA-1 
antibodies during an acute illness rules out primary EBV infection. In general, the 
vast majority of EBV infections in immunocompetent patients can be staged by 
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assaying a blood sample for VCA IgM, VCA IgG and EBNA-1 antibodies. 
Western blots or immunoblots can be used to confirm results of screening tests 
and also stage EBV infections (95, 96).  
 Measurement of IgG antibodies against EBV early antigen (EA) are not 
useful for the diagnosis of primary infection because only 60—80% of acutely ill 
patients are positive and EA antibodies can be found for years in 20% of healthy 
individuals (93, 97). When the available antibody data do not distinguish the 
stage of an EBV infection, IgG avidity assays may be useful (95, 98). The 
principle is that during the course of infection, antibodies with high binding 
strength to their target are selected. In other words, IgG antibodies during the 
acute phase of infection do not bind to their target as tightly as antibodies 
produced during convalescence. Low avidity antibodies can be dissociated from 
their target by exposure to urea or another chaotropic reagent. Avidity is 
determined by comparing the amount of antibody detected with and without urea 
treatment.  
  The best test for diagnosing and monitoring EBV infections in the 
immunocompromised host is the blood viral load (or quantitative EBV DNAemia 
assay) usually performed on a PCR platform (99). Most of these infections are 
not primary but there are a few that are and result in classic infectious 
mononucleosis. The monitoring concept is to anticipate the risk of impending 
EBV disease based on sequential changes in blood viral load. A threshold 
amount, which varies from center to center, is established that triggers 
intervention with changes in immunosuppressive and/or antiviral drug regimens. 
24 
 
Genetic Susceptibility 
Given the disparities in antibody prevalence among populations of 
different racial backgrounds observed in surveys of children in the United States, 
there may exist variances in the genetic susceptibility of certain race/ethnicities to 
EBV. This theory is supported by the incidence of infectious mononucleosis in 
family groups. A study examining infectious mononucleosis concordance in twins 
from the California Twin Program found monozygotic twins were twice as likely to 
both develop infectious mononucleosis than were dizygotic twin pairs. When the 
analysis was limited to same sex dizygotic twins, the risk in those groups was 
higher (100). These findings were then further expanded to include first-degree 
relatives in a large study of Danish families surveyed by governmental registries. 
The rate ratios for same sex twins were highest, followed by groups of siblings 
(50). It is important to note that siblings tend to have similar environments and 
behaviors, which may explain why the degree of concordance is so high. 
 Further evidence lends credence to a genetic basis for susceptibility to 
infectious mononucleosis. Recently, the HLA locus was identified as a major 
factor influencing antibodies to EBNA-1 in large Mexican American families (101). 
Although the authors interpreted this to be a genetic influence on susceptibility to 
EBV infection, not all individuals who are infected with EBV make a strong 
antibody response to EBNA-1. Therefore it is possible that the HLA locus 
influences the response to infection rather than the infection rate per se. In 
regard to infectious mononucleosis, the effect on the adaptive response to 
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primary infection may be sufficient to influence whether or not primary infection is 
symptomatic. Class II MHC is also required for viral entry into the cell, although 
whether or not there are alterations in viral entry efficiency between HLAs 
prevalent in different racial groups has not been explored. 
 
Immune Responses to EBV 
The viral dynamics and EBV-specific antibody responses during primary 
EBV infection are illustrated in Figures 1-2 and 1-3. High viral loads in both the 
oral cavity and blood are detected around the time of symptom onset in infectious 
mononucleosis and accompanied by production of IgM antibodies to EBV VCA 
and an extraordinary expansion of CD8 T lymphocytes (14). Of particular interest 
is the response of cytotoxic CD8 T cells, which have been shown to be important 
in the control of EBV infected B cells as evidenced by the disease that occurs in 
patients who lack elements of CD8 T cell function such as the ability to interact 
with and kill infected B cells (102, 103).  
During infectious mononucleosis when there are very high numbers of 
circulating CD8 T cells, many of these cells are EBV specific and directed toward 
lytically expressed proteins from the immediate early and early stages of the lytic 
cycle with particular predilection for the immediate early. Cells specific for some 
late antigens tend to emerge only after the patient has been infected for some 
time as discovered by generating T cell clones from infectious mononucleosis 
patients (104). The case of latency, however, is rather different and is often 
dependent on the relevant HLA type of the EBV infected individual in question. 
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Immunodominant epitopes for the most prevalent HLA types generally include 
those derived from latently expressed proteins, especially EBNA-2 and EBNA-3, 
although some patients develop a strong population of CD8 T cells specific for 
less readily expressed antigens such as EBNA-1 (105, 106).  
 Both CD8 and CD4 T cells require cell-to-cell contact in order to become 
activated and perform related functions (107, 108). Although total CD4 numbers 
do not increase appreciably during infectious mononucleosis, evidence exists to 
support the concept that CD4 T cells are activated and help control infected B 
cells. Using major histocompatability complex (MHC) II tetramers, it was shown 
that several lytic antigens are recognized by CD4 T cells during acute infection 
and that these cells are maintained at low levels in the blood of EBV infected 
hosts (109). That study also revealed that the response to different antigens 
varies: CD4(+) T cell responses to EBNA1 did not develop until much later, which 
likely explains the delay in EBNA1 IgG antibody responses. 
Natural killer (NK) cells are also emerging as important players during 
infectious mononucleosis. Several immunodeficiences involving T and NK cells 
and/or their cytolysis pathways result in severe EBV related outcomes (110, 111). 
These include familial hemophagocytic lymphohistiocytosis 2 (FHL2), X-linked 
lymphoproliferative syndrome (XLP), XIAP deficiency, and X-linked 
immunodeficiency with Mg+2 defect (XMEN) disorders, and are discussed in 
detail later in this chapter. 
The value of NK cells specifically, was suggested by the observation that 
NK cells preferentially killed EBV infected cells as the virus entered the lytic cycle 
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(112). The role of NK cells in vivo was investigated using a humanized mouse 
model, where NOD-scid γc-/- (NSG) mice were reconstituted with CD34+ lin- 
hematopoietic stem cells (113, 114) and infected with the B95.8 strain of EBV 
and monitored for signs of infectious mononucleosis such as CD8 lymphocytosis 
and viremia. Animals depleted of NK cells experienced more severe EBV related 
disease (115). It is interesting to note that NK depletion after an established EBV 
infection did not have significant effects, in contrast to the effect of depletion 
before infection. Given the gap in the robustness of responses observed between 
tonsillar and peripheral blood NK cells, it is possible that peripheral NK cells 
during the systemic infectious mononucleosis phase are less important than 
those during early infection in the oropharynx (116). Indeed, studies in humans 
have disagreed about the state of NK cells in peripheral blood during infectious 
mononucleosis. Work from Williams et al. showed an inverse correlation between 
NK cell numbers in the periphery and virus in the blood (117). In contrast, a 
larger prospective study found a positive correlation (14). Thus, the interplay 
between NK cells and blood virus in human subjects needs further study. Of 
course, the specific type or subset of NK cells may be more important than total 
numbers. NKG2C+ NK cells have been shown to specifically respond to and play 
a crucial role in immunity to cytomegalovirus (118). However, NKG2C+ NK cells 
do not expand upon EBV infection (119). Rather NK cells expressing NKG2A and 
CD54 could be found in higher numbers in the tonsils of EBV carriers (120) and 
in the peripheral blood during acute infection (119). In a study of pediatric 
infectious mononucleosis patients, it was recently shown that CD56dim NKG2A+ 
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KIR- NK cells preferentially proliferate in response to EBV infected cells during 
acute infection (121). 
EBV also seems to have evolved mechanisms to interfere with the 
activation of NK cells during viral replication. The protein encoded by the EBV 
open reading frame BILF1 downregulates expression of HLA-A and HLA-B on 
the surface of infected cells but not HLA-C, which is inhibitory to NK cells (122). 
Several specific populations of NK cells have been implicated in limiting the 
transformation of B cells by EBV in vitro. When exposed to dendritic cells (DCs) 
prepared with EBV, CD56bright CD16- NK cells were preferentially primed and 
were able to limit B cell transformation in vitro in an interferon (IFN) γ dependent 
manner. Interestingly, tonsillar NK cells were much more efficient than NK cells 
derived from peripheral blood (116, 123). Further understanding of NK cell 
recognition of EBV infected cells and their responses during human infection are 
needed at this point.  
Despite our growing understanding of the innate and adaptive immune 
response to EBV, it remains unclear why primary EBV infection leads to 
infectious mononucleosis in adolescents yet is most often asymptomatic in young 
children. It is possible that adolescents receive a larger initial virus inoculum 
when transmission occurs through deep kissing. Our studies did not reveal any 
correlation between virus copy number in the oral cavity and severity of illness 
(14), however peak virus copy number in the oral cavity may not directly reflect 
the initial virus inoculum, nor is it possible to measure the initial virus inoculum 
with natural infection. Another idea put forward is that infectious mononucleosis 
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in adolescents may reflect the response of cross-reactive memory CD8 T cells. 
For example influenza specific CD8+ T cells might cross-react with EBV (124) 
and as adolescents are presumably more likely to have high numbers of 
influenza specific CD8 T cells, they could react more strongly with EBV. However, 
we have not seen evidence of influenza-EBV dual specific CD8 T cells in our 
cohort (68) and it remains debatable whether pre-existing (cross-reactive) CD8 T 
cell immunity to EBV would increase or decrease in severity of infectious 
mononucleosis. A CD8 T cell peptide epitope vaccine was effective in generating 
EBV specific CD8 T cell responses, and there was no incidence of infectious 
mononucleosis in the vaccinated group, although the study was small (125). An 
exciting proposition has arisen from recent data that implicate NKG2A+ NK cell 
as important in EBV control (119, 121). Azzi and colleagues showed that CD56dim 
NKG2A+ KIR- NK cells were found at significantly lower levels in the peripheral 
blood of adolescents and adults compared to children, suggesting that decreased 
NK mediated immune control of EBV could explain why adolescents and adults 
experience infectious mononucleosis more frequently than do children. 
 During the convalescent period of infectious mononucleosis (3 to 6 
months postinfection), the number of CD8+ T cells declines to normal levels (14). 
Previous work in mice suggested that infection with hepesviruses may cause 
long term changes to the “readiness” of host immune cells, thus priming them for 
subsequent bacterial infections (126). These effects were later shown to be 
transient in that model (127), but work in human subjects showed that there were 
no long-term gene expression changes observable in peripheral blood 
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mononuclear cells following acquisition of EBV (87). The virus is maintained in 
resting memory-like B cells. Probably the most interesting phenomenon that 
occurs during this phase of infection is related to the levels of antibody that are 
produced and maintained by latently infected hosts.  
Some peculiar trends exist in the antibody response to EBV. For example, 
antibodies against EBNA-1 display an unusually long delay between virus 
acquisition and the presence of anti-EBNA-1 IgG, as it generally appears only 
after a patient with infectious mononucleosis has convalesced (128, 129). This is 
especially odd given the high levels of class switched antibody toward EBV 
antigens that can be measured in many patients presenting with infectious 
mononucleosis, including responses to latently expressed gene products of 
EBNA-2 and EBNA-3 (109) (Figures 1-2 and 1-3). The delayed kinetic might be 
associated with alanine-glycine rich regions within the structure of EBNA-1’s 
protein product, which has been shown to inhibit proteosomal processing of 
relevant epitopes (130). That this is the case, however, is not clear and may have 
to do more with accumulation of protein released from cells for cross 
presentation. In contrast, high levels of antibody specific for the immediate early 
antigen BZLF1 are maintained for the life of the host. This is likely because 
BZLF1 is expressed by cells undergoing viral reactivation and thus is more 
frequently presented to B cells in latently infected hosts in comparison to proteins 
that are expressed later in the viral replication process (131). 
 
Primary Immunodeficiencies 
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X-linked lymphoproliferative syndrome (XLP) is a disease characterized by 
anemia, hypergammaglobulinemia and lymphohistiocytosis. Generally the boys 
that present with this disease exhibit massive cellular responses to primary EBV 
infection that results in hemophagocytic pathology, even though they are 
simultaneously unable to control EBV transformed B cells (132). It was then 
discovered that the main deficiency involved with XLP is in the SLAM family 
member slam associated protein (SAP), which is encoded by the human gene 
SH2D1A. Mutations in this gene disrupt the ability of T cells and NK cells to 
interact with B cells, resulting in a lack of immunoglobulin class switching and 
meaning T cells and NK cells cannot recognize B cell targets to induce death 
(133, 134). A study of XLP patients showed through random X chromosome 
inactivation that only CD8 T cells that have a functioning copy of SH2D1A in 
mothers of boys with XLP are able to kill EBV infected B cells (102) and that boys 
with CD8 T cells that spontaneously recover SAP expression have much better 
outcomes (135). A similar disease exists in the form of XIAP deficiency, which 
causes a defect in the function of caspase activity, and thus cell mediated 
cytotoxicity. Patients who lack functional XIAP also have difficulty controlling EBV 
infected cells, because they also cannot induce lysis of EBV infected targets 
(132).  
The Fcγ receptor CD16 is necessary for proper NK cell function by 
allowed for cytolysis of target cells in an antibody dependent manner. It was first 
recognized that some patients with recurrent infections, including herpesviruses, 
had a mutation in the gene encoding CD16 (136, 137). Later it was discovered 
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that the specific homozygous missense mutation involved caused CD16 not to 
associate with its signaling partner CD2 on the cell surface. Thus, signaling 
through CD16 to induce spontaneous NK cell cytoxicity was eliminated even after 
engagement of CD2 (138). 
Another X-linked syndrome observed in boys involves the magnesium 
transporter MAGT1 and is known as X-linked immunodeficiency with magnesium 
defect, EBV infection, and neoplasia (XMEN). Patients affected presented with 
defects in T cell activation as well as high EBV viral loads and over time 
developed EBV related disease (139). Sequencing of the X chromosome in two 
brothers revealed that both had a deletion in the region of MAGT1. Impaired 
magnesium transport resulted in reduced signaling following antigen receptor 
engagement, particularly interfering with calcium flux which is necessary during T 
cell activation (140). Investigators then isolated cells from several patients with 
similar symptoms and supplemented their media with magnesium, thereby 
restoring much of the NK and T cell function to these cells. Results were later 
extrapolated to dietary supplements in XMEN patients, and helped abrogate 
related symptoms (141).  
Serine threonine kinase 4 (STK4) is required for the activation of the 
forkhead box proteins FOXO1 and FOXO3. Both of these transcription factors 
have important roles in T cell homing, function, and homeostasis, especially 
during persistent viral infections (142-145). Without functional STK4, these 
patients experience recurrent episodes of herpesvirus reactivation, in particular 
those with cutaneous manifestations such as HSV and VZV. Approximately half 
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of patients presenting with STK4 mutations also have difficulty controlling EBV 
and have EBV related B cell pathologies. Successful treatments for STK4 
deficiency have included anti-CD20 and hematopoietic stem cell transplant (146). 
Another protein known to affect the response to primary EBV infection is the TNF 
receptor family member CD27. Patients from three independent families 
presenting with severe primary EBV infection or EBV related lymphoproliferative 
disease were found to have a homozygous mutations in the gene encoding 
CD27. It was initially thought that the role of CD27 must be related to its 
expression in regard to the development of T or B memory phenotype B cells, but 
this was found not to be the case (147, 148). What exactly drives disease in 
these instances is not well understood.  
 
EBV Associated Diseases 
 EBV has been shown to be the causative agent of about one percent of 
the worldwide human cancer burden. In particular, EBV infection is associated 
with neoplasia of lymphoid origins including endemic Burkitt’s lymphoma (eBL) 
and Hodgkin’s lymphoma (HL), and epithelial origins including nasopharygeal 
carcinoma and gastric carcinoma. EBV is considered the etiologic agent in 95% 
of cases of eBL, which occur in regions where malaria is common (149). 
Likewise, EBV can be detected in a high proportion of HL cases in 
underdeveloped nations, but accounts for less than half of cases in Western 
countries (150). It is important to note that incidence of infectious mononucleosis 
is exceptionally low in Southeast Asia and equatorial Africa where EBV infection 
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during childhood is nearly ubiquitous, thus it might be extrapolated that infectious 
mononucleosis does not have a strong correlation with either eBL or HL in these 
areas (151). Emerging evidence suggests that previous presentation with 
infectious mononucleosis can increase the risk of HL (58). While associations 
between infectious mononucleosis and epithelial carcinomas have not been 
explored, the presence of EBV in tumors from nasopharyngeal and gastric 
carcinoma patients is well documented. About 10% of human gastric carcinomas 
are EBV positive (152). Like eBL and HL seen in underdeveloped nations, 
nasopharyngeal carcinomas from endemic regions are virtually all positive for 
EBV DNA (153), with these tumors thought to be derived from a single EBV 
infected epithelial cell (154, 155). 
It is possible that achieving a very high viral titer in the blood at any point 
in life predisposes individuals to subsequent EBV related cancers. For example, 
patients who present with eBL and endemic nasopharygeal carcinomas live in 
malaria endemic areas. Evidence shows that patients being treated for malarial 
disease can have extremely high titers of EBV in the blood (156). Titers of this 
magnitude are seen exclusively in patients presenting with infectious 
mononucleosis in developed countries. Thus, it may be possible to reduce 
occurrences of cancer with prophylactic or therapeutic vaccines aimed at 
preventing primary EBV infection or at the very least reducing the set point at 
which the virus is maintained in these individuals. 
In recent years, infectious diseases have been emerging as possible 
triggers for autoimmune disorders. EBV infection in particular has come to be 
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highly associated with occurrence of MS. EBV as a causation factor in MS was 
first proposed over thirty years ago (157). Many correlative observations for this 
trend exist, including a low incidence of infectious mononucleosis and MS in 
developing countries, and MS usually first manifests after the adolescent years 
during which EBV would be acquired, increasing at a rate of 11% per year 
following primary EBV (57). There is also a high association between patients 
who recall having infectious mononucleosis and subsequent development of MS 
(158-160). Furthermore, MS in EBV negative individuals occurs very infrequently 
(41, 161).  
A causative role for EBV was supported by examination of the antibody 
profiles of patients with MS, scrutinizing the viral loads, epitope specificity, and 
quantity of antibodies, especially those against EBNA. The risk of MS increases 
positively with levels of circulating anti-EBNA antibodies (162-165). The ability to 
discriminate MS cases and controls was substantially enhanced by the inclusion 
of quantitative measures of the anti-EBNA-1 response to EBV infection (166). 
Higher loads of EBV DNA can also be found in the cerebrospinal fluid of patients 
with relapsing remitting MS as compared with controls (167). Interestingly, the 
strong genetic association of MS with particular human leukocyte antigen (HLA) 
alleles primarily reflects the association with anti-EBV responses (101). 
Researchers recently treated an MS patient with autologous T cells expanded by 
exposure to EBV antigens. Transfer of the EBV specific CD8 T cells resulted in a 
decrease in anti-EBV antibody titres as well as in the size and number of MS 
related lesions in the brain (168).   
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Animal Models 
One of the major barriers to studying many human viruses is the lack of a 
small animal model. EBV belongs in this group because it only infects primates. 
Although studies have been performed with murine gammaherpesvirus-68 (MHV-
68) there are important genetic differences between that virus and EBV. In order 
to directly evaluate the effects of EBV on various lymphoid compartments in vivo, 
efforts toward developing feasible methods for modeling human infections have 
resulted in the creation of humanized mice. Humanized mice have only become 
a viable option for studying human diseases within the last ten years or so due to 
low engraftment of human cells even in animals with severe combined 
immunodeficiency (SCID) or knockout of one of the recombinase activating 
genes (RAG). With the advent of common gamma chain (a receptor component 
for IL-2, 4, 7, 9, 15, and 21) knockouts and appreciation of non-obese diabetic 
mouse polymorphisms that influence phagocytosis, engraftment improved 
dramatically. 
 The two types of mice most commonly employed are the previously 
mentioned NSG and the BALB/c RAG-/- γc-/-. Cells derived from either human 
fetal liver, human fetal thymus, or CD34+ hematopoietic stem cells are then 
transferred into neonatal mice to reconstitute their immune systems (169). Of 
these two mouse strains, the NSG mouse has more complete reconstitution of 
the T and NK compartments and could be maintained for 22 weeks with latent 
virus detectable and without developing tumors or other EBV related pathology 
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(170). This model has also been shown to give an approximation of human 
immune components (113, 114). Mice are bred onto a transgenic HLA 
background. This then allows for thymic selection of the human derived cells and 
later specific responses during infection of these animals with EBV (171, 172).  
It is important to note, however, that study of EBV within this context may neglect 
important aspects of interplay between EBV and epithelial cells, which have been 
shown to be important during the replication of EBV, chiefly within the oropharynx 
(23). Nevertheless, humanized mice represent a significant step forward to 
investigating cellular responses in vivo.  
 In particular, the roles of certain subsets of cells have been interrogated 
through the depletion of these populations prior to infection with EBV. A 
significant gap in our understanding of the early innate response to EBV existed 
and had only been addressed in vitro prior to the advent of this model. Using the 
NSG mouse and virus obtained from the B95-8 cell line, investigators can now 
effectively emulate events that occur early during infection in the peripheral blood. 
Humanized mice exhibit classical features of infectious mononucleosis such as 
elevated CD8 T cell counts and high levels of IFNγ (115). Specific deletion of 
subsets of NK cells could then be performed to examine which were most 
important during the response to primary EBV infection. Furthermore, the roles of 
adaptive immune cells may be examined as well. Investigators looking at CD4 
and CD8 T cells found EBV specific T cells were HLA restricted and responded 
to autologous lymphoblastioid cell lines. When either CD4 or CD8 T cells were 
depleted from these mice, the mice developed EBV related pathologies (170). 
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These results are not particularly surprising given the same pattern can be 
observed in primary human immunodeficiencies as previously described, but 
they provided important evidence that the humanized mouse can be an 
appropriate tool for asking questions about the response to EBV. Mouse models, 
however, neglect nearly all aspects of initial infection as events in the oral cavity 
cannot occur as EBV does not have tropism for murine epithelial cells. In order to 
examine infection of the tonsil and oral epithelium, primate models might be 
preferred as there is established infection in the oral cavity similar to EBV in 
humans. 
 Studies from Japan have suggested that EBV infection may be modeled in 
rabbits (173, 174). Animals in these studies were alternately inoculated 
intravenously, intranasally, and perorally with EBV derived from the B95-8 cell 
line. Most animals had only transient levels of virus detectable in the blood, but 
two had consistent viral titers. Both T and B cells appeared to be infected in 
these incidences (173, 174). It is important to note that while early antigen IgG 
titers were maintained, VCA IgG antibodies were transient even when very high 
quantities of virus were used (174). Though not a model of infection with a great 
deal of similarity to infectious mononucleosis, rabbits may still provide interesting 
insight with regard to the kinetics and magnitude of antibody responses to EBV, 
which has implications for the development and testing of humoral component 
vaccines such as the gp350 subunit vaccine.  
Non-human primates are the other major option for investigating EBV 
infection in vivo. The gamma herpes virus LCV exists in two types: that which 
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infects old world and that which infects new world primates. The LCV that infects 
old world primates has higher genetic similarity to EBV than new world LCV. The 
open reading frames of rhesus LCV have 28-98 % amino acid identity with EBV 
(175). Thus, rhesus LCV is used to model EBV in rhesus macaques. The 
symptoms of EBV and LCV infection are very similar, and LCV can be given 
orally to emulate natural infection routes in humans. One difference is that the 
incubation period of LCV is generally shorter, lasting about three weeks rather 
than six.  
 LCV can be manipulated using a bacterial artificial chromosome system to 
allow for mutation of the LCV genome. This enables researchers to examine the 
possible effects of EBV homologues in vivo. For example, BARF-1 has been 
shown to bind and inhibit the signaling of colony stimulating factor 1 (176, 177), 
which can promote the maturation and maintenance of type I interferon 
producing plasmacytoid DCs (178). Knocking out BARF-1 in LCV resulted in 
more favorable outcomes and lower viral loads in infected rhesus macaques 
(179). 
 The LCV model can also be used to test potential prophylactic or 
therapeutic vaccines. An LCV gp350 subunit vaccine protected against infection 
and reduced the viral set point in rhesus macaques (180). More recently, 
Leskowitz and colleagues showed that an adenovirus based vaccine encoding 
LCV EBNA-1 induced expansion of CD4+ and CD8+ T cells specific for EBNA-1 
in rhesus macaques with natural persistent LCV infection (181). 
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Therapeutics and Prophylactics 
Given the disease burden associated with acute and chronic EBV diseases, 
development of an EBV vaccine has long been a priority for researchers in the 
field. The National Cancer Institute recommended that more clinical trials be 
conducted to test the safety and efficacy of a vaccine to prevent infectious 
mononucleosis and cancers caused by EBV (61). Although the first phase 1 trial 
for a prophylactic EBV vaccine occurred almost twenty years ago (182), there 
has been relatively little progress since. In total, three prophylactic vaccines have 
been tested in humans, and although all proved at least moderately 
immunogenic, none provided sterilizing immunity (183). However, sterilizing 
immunity is probably not necessary to impact symptomatic disease caused by 
primary EBV infection. For example, a phase 2 trial in Belgium showed that 
vaccination with a gp350 subunit adjuvanted vaccine reduced the number of 
cases of infectious mononucleosis (184).  
 Whether or not a vaccine exclusively targeting gp350 is sufficient to 
prevent EBV related disease, however, is unknown. In the case of epithelial 
neoplasia, it seems less convincing on the grounds that gp350 is not strictly 
required for viral entry into epithelial cells and can be achieved via the viral 
proteins gH and gL, albeit less efficiently (30). However, it is possible that 
preventing B cell infection in vivo could impact epithelial infection, given EBV’s 
interesting switch tropism. Increasing the range of the vaccine to include other 
proteins necessary for epithelial entry such as the aforementioned gH or gL, 
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might improve the efficacy of a vaccine with the goal of preventing EBV positive 
lymphomas and carcinomas. 
 
Treatment 
There is no currently accepted specific treatment for infectious mononucleosis. 
While it is clear that acyclovir and valacyclovir and have an antiviral effect in vivo, 
a clinical benefit has not been convincingly demonstrated to date (185). 
Ganciclovir and valganciclovir have been used treat EBV infections in 
immunocompromised hosts but there are no controlled trials demonstrating 
clinical efficacy. Corticosteroids are often prescribed to treat inflammatory 
complications such as airway obstruction or autoimmune phenomena such as 
anemia and thrombocytopenia, but the value of these drugs is controversial and 
they may impair clearance of the viral load (186).  
 
Thesis Statement 
EBV is one of the most important human pathogens. Although this virus 
was discovered more than 50 years ago and infects more than 90% of the 
worldwide population, there are large gaps in our knowledge of its epidemiology 
and pathogenesis. Our future challenge is to focus research on the following five 
gaps. 
 1. We don't know how EBV is transmitted to young children.  
 2. We don't know why some adolescents and young adults become very ill 
from a primary EBV infection while others remain completely asymptomatic. 
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 3. We don't have an approved specific treatment for EBV infections. 
 4. We don't have an approved EBV vaccine. 
 5. Finally, we don't know the mechanism by which EBV induces 
malignancies or autoimmune diseases. In terms of EBV-associated cancer, we 
do know a reasonable amount about how this virus infects and transforms 
lymphocytes and epithelial cells. What we don't understand is how these cells 
escape immune recognition. 
 This thesis attempts to address these issues by using systems biology 
and cellular phenotyping to examine both the incubation period and acute 
symptomatic phases of EBV related infectious mononucleosis. Overall, we have 
found that there are several previously uncharacterized virological and 
immunological events that occur prior to symptom onset. First, EBV disseminates 
from the oral cavity to the periphery much earlier than previously thought, 
presumably in latently infected “Latency 0” B cells. Second, a type I IFN 
signature occurs most robustly before symptom onset and occurs concurrently 
with dissemination of virus to the periphery. Third, plasmacytoid dendritic cells 
are significantly diminished in numbers and frequency in the circulation up to ten 
days before symptom onset and do not recover for a number of weeks.  
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Chapter 2 
Primary EBV infection induces an expression profile distinct from other 
viruses but similar to hemophagocytic syndromes 
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Abstract 
Epstein-Barr Virus (EBV) causes infectious mononucleosis and establishes 
lifelong infection associated with cancer and autoimmune disease. To better 
understand immunity to EBV, we performed a prospective study of natural 
infection in healthy humans. Transcriptome analysis defined a striking and 
reproducible expression profile during acute infection but no lasting gene 
changes were apparent during latent infection. Comparing the EBV response 
profile to multiple other acute viral infections, including influenza A (influenza), 
respiratory syncytial virus (RSV), human rhinovirus (HRV), attenuated yellow 
fever virus (YFV), and Dengue fever virus (DENV), revealed similarity only to 
DENV. The signature shared by EBV and DENV was also present in patients 
with hemophagocytic syndromes, suggesting these two viruses cause 
uncontrolled inflammatory responses. Interestingly, while EBV induced a strong 
type I interferon response, a subset of interferon induced genes, including MX1, 
HERC5, and OAS1, were not upregulated, suggesting a mechanism by which 
viral antagonism of immunity results in a profound inflammatory response. These 
data provide an important first description of the response to a natural 
herpesvirus infection in humans.  
 
Introduction 
Epstein-Barr virus (EBV) is a herpesvirus that causes lifelong infection in 
humans. EBV is estimated to be a causative agent in 1% of all human cancers, 
(187) including various lymphomas, and nasopharyngeal and gastric carcinomas; 
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(188) and to contribute to autoimmune diseases such as systemic lupus 
erythematosus (SLE) (189) and multiple sclerosis. (190) Nonetheless, the most 
common consequence of EBV infection is infectious mononucleosis (IM). (35) 
Primary acquisition of the virus by children before puberty does not generally 
cause recognizable symptoms, but those who become infected during or after 
adolescence have a high likelihood of developing IM. EBV infection is trending 
older, particularly in developed countries, (51) and IM represents a growing 
health issue. There is currently no vaccine and no effective treatment for EBV 
infection. IM is distinct from acute infection with other viruses in that it is 
characterized by a lengthy incubation period and severe lymphocytosis. The 
incubation period for EBV is about six weeks in length, (13) contrasting starkly 
with symptomatic viral illnesses such as influenza where the incubation period is 
only a few days. In addition, the lymphocytosis observed in IM reflects a profound 
activation and expansion of EBV specific, and to a lesser extent, bystander CD8+ 
T cells. (68, 106) 
In order to gain insight into EBV pathogenesis, we examined the host 
response to EBV using a genomic approach. Systems biology is emerging as an 
important tool for understanding the human response to infection that can 
provide novel means of diagnosis and insight into disease mechanisms. (191) 
Recent studies have reported genomic changes occurring in B cells infected with 
EBV in vitro (192) or EBV+ Burkitt Lymphoma cell lines. (193) However, there is 
a dearth of understanding in current research about the host gene changes that 
occur during natural viral infection with EBV in otherwise healthy humans and 
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whether or not these infections lead to long lasting changes in the immune 
system. We sought to address these issues by performing transcriptomic studies 
on human subjects participating in a prospective study of primary EBV infection 
acquired naturally. We then compared these data with gene expression analyses 
of other acute viral infections, systemic illnesses, and interferon (IFN) driven 
immune responses. We found the human immune response to EBV has a 
distinct and reproducible gene expression signature that more closely resembles 
the dysregulated innate immune responses observed during cytokine storm 
illness than what is seen during other acute viral infections. Furthermore, we 
identified a subset of genes that represent likely targets of viral immune evasion 
mechanisms. 
 
Results  
Prospective analysis of EBV infection in young adults 
EBV naïve subjects were recruited from freshman classes at the 
University of Minnesota during 2006 and 2007. Enrolled study subjects were 
screened for exposure to EBV on an ongoing basis by testing blood or throat 
wash samples taken every four to eight weeks. Samples were evaluated for EBV 
genomes by qPCR and/or antibodies to viral antigens. Of 143 subjects followed 
in the study, 66 experienced primary EBV infection during their undergraduate 
years. (194) 
Due to the long incubation period, the exact date of viral acquisition is not 
known. Instead, date of symptom onset was used for timing, since this date was 
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well defined for each subject. For acute microarray analysis, we chose eight 
subjects with peripheral blood samples taken near the onset of symptoms, and 
compared them to samples taken at least three months before infection. These 
eight subjects plus an additional two were chosen for analysis of latency, with 
latent samples being defined as at least >200 days after infection (Table 2-1). 
Baseline and latency samples were chosen from timepoints when the subjects 
did not report symptoms of any other illness and had not reported illness for at 
least two weeks prior. Further analysis was performed by PCR on an additional 
44 subjects following initial evaluation of these eight by microarray as described 
below. 
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*  Day relative to symptom onset       
#  IgM or IgG antibodies to EBV viral capsid antigen      
**  Copies/mL of viral DNA detected in oral cells or whole blood     
Values in parentheses are implied, based on values in adjacent timepoints (not shown) 
 
Patient ID  PRE  ACUTE  LATENT 
5027 Day* -137  -15  566 
SOI 5 VCA IgM# (-)  -   
Gender Female VCA IgG# -  -  +++ 
Duration 42 days Oral virus** (-)  800  11400 
CMV neg Blood virus** (-)  -  - 
5088 Day -118  -4  406 
SOI 4 VCA IgM (-)  -   
Gender Male VCA IgG -  -  +++ 
Duration 21 Oral Virus (-)  15,000  - 
CMV neg Blood virus (-)  -  - 
5509 Day -119  -4  563 
SOI 3 VCA IgM (-)  -   
Gender Female VCA IgG -  -  (+++) 
Duration 8 days Oral Virus (-)  42,500  - 
CMV neg Blood virus (-)  18,800  - 
5342 Day -115  0  704 
SOI 4 VCA IgM (-)  + / -   
Gender Female VCA IgG -  -  +++ 
Duration 27 days Oral Virus (-)  67,000  1300 
CMV neg Blood virus (-)  5,000  - 
5483 Day -97  3  231 
SOI 3 VCA IgM (-)  +++   
Gender Female VCA IgG -  -  +++ 
Duration 25 days Oral Virus (-)  27,300  - 
CMV neg Blood virus (-)  4,400  - 
5036 Day -139  2  341 
SOI 4 VCA IgM (-)  ++   
Gender Male VCA IgG -  -  (++) 
Duration 19 days Oral Virus (-)  1,000  4400 
CMV neg Blood virus (-)  11,400  - 
5524 Day -132  7  547 
SOI 4 VCA IgM (-)  +++   
Gender Female VCA IgG -  +++  (+++) 
Duration 66 days Oral Virus (-)  49,900  - 
CMV pos Blood virus (-)  60,000  - 
5324 Day -92  14  420 
SOI 5 VCA IgM (-)  +++   
Gender Male VCA IgG -  -  +++ 
Duration 15 days Oral Virus (-)  2,500,000  1200 
CMV pos Blood virus (-)  200  - 
5139 Day -157   534 
SOI 2 VCA IgM (-)    
Gender Male VCA IgG -   (+++) 
Duration 15 days Oral Virus (-)   - 
CMV pos Blood virus (-)  
No 
sample 
 - 
5370 Day -94   354 
SOI 3 VCA IgM (-)     
Gender Female VCA IgG  -    (+++) 
Duration ND Oral Virus (-)    700 
CMV neg Blood virus (-)   
No 
sample 
 200 
  Average -120  0  467 
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Table 2-1.  EBV-naïve freshman were enrolled in a prospective clinical study and 
followed over the course of their undergraduate education. Samples were 
collected at multiple intervals before, during, and after primary infection with EBV. 
Of 66 subjects, 10 were selected for microarray analysis. Anti-EBV antibody titers, 
EBV viral loads, and other patient information for the “PRE” “ACUTE” and 
“LATENT” timepoints are shown. SOI, Severity of illness; Duration is days of 
symptoms.  
 
Primary EBV infection produces a distinct gene expression signature in 
peripheral blood during acute infection but not during latency 
 Microarray analysis was performed on peripheral blood mononuclear cells 
(PBMCs) from subjects described above. Each was compared with his or her 
own healthy pre-infection sample. Gene expression fold changes greater than 2, 
with a p-value of ≤ 0.05 with Bonferonni multiple tests correction were considered 
significant. For subjects presenting with acute IM, this analysis yielded a list of 
464 genes that changed more than two fold (Figure 2-1A and Appendix Table A-
1). 318 genes were upregulated and 146 genes were downregulated. Of the 
genes changed during acute IM, one of the largest constituent functional groups 
was found to be cell cycle by Ingenuity Pathway Analysis (Figure 2-1B)(Figure 
1B). Likewise, pathways such as mismatch repair, DNA damage response, and 
ATM signaling, are associated with highly proliferative populations. Genes 
associated with interferon signaling were significantly enriched in the acute gene 
list, reflecting the host response to viral infection. Finally, pathways representing 
various immune functions, such as granzyme signaling, antigen presentation, NK 
function, and complement were enriched in the acute EBV gene list (Figure 2-1B). 
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Figure 2-1. A distinct gene expression profile is apparent during acute EBV 
infection, but not latent infection. (A) Microarray analysis was performed on 
pre-infection, acute, and latent timepoints for the 10 subjects with primary EBV 
infection (listed in Table S1). 464 genes were shown to be significantly changed 
during the primary response to EBV at a fold change of ≥ 2 and a p-value ≤0.05. 
No genes were significantly changed during the latent phase of infection using 
the same criteria. (B) Ingenuity Pathway Analysis of the 464 acute genes 
revealed 14 pathways that were enriched amongst the genes that changed 
during primary EBV. These had a significant p-value (the negative log is shown) 
following evaluation with the Benjamini-Hochberg multiple tests correction. (C) A 
heatmap representation of the highest (≥ 3 fold) gene changes during the acute 
and latent stages of EBV infection.  
 
Studies in mice showed that latent herpesvirus infection protected hosts 
from subsequent bacterial infection, suggesting that persistent infection with 
herpesviruses may have a beneficial role in their human hosts (127, 195). Thus, 
we wanted to determine if long-term gene changes were measureable in human 
subjects after they had acquired primary EBV. In contrast to acute infection, 
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subjects with latent infections yielded no significantly changed genes compared 
with pre-infection (Figures 2-1A/C and data not shown). This approach is highly 
sensitive as each subject’s latent infection sample was compared with his or her 
own pre-infection sample. Nonetheless, there were no gene changes that met 
significance criteria, even IFNG, which was shown to be elevated in mice latently 
infected with a murine gammaherpesvirus. (195) 
 
Different cell types contribute to the gene expression signature during IM  
 We chose to perform analysis of whole PBMCs in this study to facilitate 
the comparison to data published on other infections and disorders (see below). 
However, we still sought to understand which cellular components were 
representing the distinct aspects of the signature observed in acute EBV infection. 
Thus, we measured gene expression in sorted CD8+ T cells, natural killer (NK) 
cells, monocytes, and B cells (Figure 2-2A) from 4 subjects using a quantitative 
PCR array of 43 genes selected from the acute microarray analysis (Figure 2-3). 
These genes comprised the three functional groups: Type I interferon regulated 
genes (IRGs), type II IRGs, and cell cycle/metabolism genes. 
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Figure 2-2. CD8+ T cells and monocytes show upregulation of key gene 
groups during acute infection. Quantitative PCR analysis was performed on 
RNA prepared from sorted cells from peripheral blood of four subjects before and 
during acute EBV infection. (A) This panel shows the staining and sorting 
strategy for separation of CD8 T cells, B cells, NK cells, and monocytes. (B) 
Each subject’s respective cell type was compared with his or her own cell type at 
the preinfection time point. All acute samples were taken from subjects within a 
week of onset of symptoms. The average fold change of both type I and type II 
IRG as well as cell cycle genes for four subjects is shown. A paired t-test was 
used for statistical analysis.  (C) Monocyte numbers were determined from 
complete blood counts of subjects at the acute and latent phases of EBV 
infection. 
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Figure 2-3. Comparison of fold changes obtained by qPCR and microarray. 
Average fold changes of eight patients between healthy baseline and acute 
sample are shown for all upregulated genes included on the qPCR array. 
Microarray values are shown in gray, qPCR values are shown in black. Error 
bars are +/- standard deviation. 
 
 All cell types displayed ≥ 3 fold upregulation of type I IRGs, suggesting 
that the interferon response during primary EBV infection is systemic, not limited 
to a particular cell type (Figure 2-2B). The cell cycle aspect of the gene 
expression signature, however, was highest in monocytes and CD8+ T cells. We 
found this result surprising given the fact that an increase in the number of 
monocytes had not been previously appreciated in IM literature. Complete blood 
counts from our subjects indicate that monocyte numbers were indeed elevated 
during IM (Figure 2-2C). Recent evidence has emerged showing IFNγ can induce 
monopoeisis, (196) thus, our data are consistent with a role for IFNγ in the 
proliferation of monocytes during primary EBV infection.  
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 Human peripheral blood has been shown to have different subgroups of 
monocytes, which may be broadly described as inflammatory M1 monocytes or 
immunoregulatory M2 monocytes. (197) Given the fact that M2 monocytes are 
induced by IL-10 and EBV produces a viral IL-10 homolog we explored the 
possibility that the increase in monocytes numbers is accompanied by a shift in 
the M1 to M2 ratio during IM. However, no major change in expression of CD163 
or HLA-DR (commonly used to distinguish M1 and M2) was found on monocytes 
during acute infection (data not shown). Thus, although monocytes are increased 
during acute infection, they may represent a heterogeneous mix of cells that 
does not fit the established M1/M2 paradigm.  
 
Comparison of EBV to other viral infections and SLE 
We compared our data on EBV with published data sets from five other 
acute viral infections including influenza A virus (Flu), human rhinovirus (HRV), 
respiratory syncitial virus (RSV), (198) dengue fever virus (DENV), (199) and 
yellow fever virus vaccine strain (YFV). (200) Additional comparison was 
performed against samples from patients with the autoimmune disease SLE, 
because EBV had been suggested to be an etiologic agent of SLE(201) and SLE 
patients have been found to express IRGs. (202) Data were also compared with 
subjects who were administered polyinosinic:polycytidylic acid (Poly IC), as an 
inducer of a classic type I interferon response. (203) A heatmap of the EBV gene 
set with a fold change (FC) ≥ 3 provided a good visual representation of this 
comparison (Figure 2-4), although a more complete gene list (FC ≥ 2) can be 
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found in Appendix Table A-1. Young adults presenting with acute EBV infection 
have a distinct gene expression pattern from those with other acute viral 
infections, SLE, or subjects administered Poly IC (Figure 2-4). Four main points 
are apparent from the heatmap: 
 
Figure 2-4. Primary Epstein-Barr virus infection causes distinct expression 
patterns in comparison to other interferon driven responses. Heatmap 
shows a list of the genes up/down regulated 3-fold during acute infection with 
EBV in comparison to subjects with other viral infections (YFV, Flu, HRV, RSV, 
and DENV), subjects injected with Poly IC, or patients with SLE. The color 
intensity represents fold changes in gene expression in comparison to either 
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each subjects’ own healthy baseline (EBV, Flu, HRV, RSV, and Poly IC) or in 
comparison to healthy controls (SLE and DENV). Data is arranged as a 
hierarchical clustering of genes. The genes shown were derived from analysis of 
EBV subjects (fold change ≥ 3 and met a statistical significance cutoff of p-value 
of ≤0.05 with Bonferonni multiple-tests correction, please see Table S2 for fold 
change ≥ 2). Each column represents a single subject. Horizontal gray bars 
indicate that the gene of interest was not present in the analyzed dataset used 
for comparison. Vertical gray bars separate disease groupings. Colored boxes on 
the right represent specific clusters of genes discussed in the text: green box and 
green asterisks--EBV unique, purple box--genes in common between EBV and 
DENV, red--genes upregulated in all situations, blue--genes down-regulated in 
EBV and some other situations. 
 
IRGs are induced in all viral infections. The greatest similarity between EBV and 
other acute viral illnesses was found amongst the genes that are outlined in the 
red box in Figure 2-4 Figure 3 (also listed in Appendix Table A-1). These genes 
are composed almost exclusively of IRGs. IRGs were defined using the online 
database Interferome and by comparison to PBMCs stimulated by IFN in vitro 
(data not shown). Not surprisingly, such genes were also upregulated by Poly IC, 
and were a dominant element of the SLE signature (Figure 2-4). (202) 
Interestingly, only a minority, 21% of the EBV gene signature was comprised of 
IRGs. This is markedly lower than Flu and YFV, where 48% and 65%, 
respectively, of the gene changes were IRGs (Figure 2-5). Further analysis via 
classification of type I IRGs and type II IRGs, showed there was fairly equal 
representation between the two IFN types for EBV. Flu and YFV, however, were 
dominated by type I IRGs, with more than 80% being regulated by type I IFN 
(Figure 2-5). Thus, while primary EBV exhibited marked upregulation of IRGs, 
they did not represent a dominant aspect of the signature, and reflected an 
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enrichment of a type II IFN response in addition to the more typical type I IFN 
response.  
 
Figure 2-5. EBV demonstrates a bias toward a type II IRG expression 
pattern. (A) Genes upregulated during acute viral infection were divided into IRG 
and non-IRG subsets. The number of genes that changed significantly are listed 
for each infection. The proportion of IRG and non-IRG are shown in the bar 
graph. (B) Only genes classified as IRG were used for this analysis. IRGs were 
separated into groupings based on relative upregulation by type I and type II IFN 
in PBMC stimulated with IFN in vitro. 
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Figure S2: EBV demonstrates a bias toward a type II IRG 
expres ion pattern 
(A) Genes upregulated during acute viral infection were divided into IRG 
and non-IRG subsets. The number of genes that changed significantly 
are listed for each infection. The proportion of IRG and non-IRG are 
shown in the bar graph. (B) Only genes classified as IRG were used for 
this analysis. IRGs were separated into groupings based on relative 
upregulation by type I and type II IFN in PBMC stimulated with IFN in 
vitro.  
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EBV unique genes. The heatmap in Figure 2-4 also shows a set of genes 
increased in primary EBV infection but not other infections (Figure 2-4), green 
box and green asterisks). We defined a total of 59 genes that were “EBV unique” 
in comparison to all other acute viral infections examined using a 2-fold increase 
cutoff for EBV (Appendix Table A-2). Given this finding, we wondered if primary 
EBV infection could be distinguished from other acute common viral illnesses. 
We conducted a small, blinded analysis of clinical samples. Analysis of 43 genes 
correctly distinguished acute EBV illness from non-EBV viral illnesses (Figure 2-
6).  
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Figure 2-6. Gene set analysis can successfully segregate the EBV signature 
from other acute illnesses. Gene expression of the indicated genes was 
determined by qPCR on 11 symptomatic subjects. Heat map indicated fold 
change from each subject’s own baseline. K-means clustering was performed on 
8 blinded samples and three known EBV samples. Analysis was performed with 
three clusters and 10,000 runs. Three samples were obtained from subjects 
presenting with acute primary EBV infection. Five additional samples were 
collected from subjects presenting with other undefined acute illnesses. The 
symptomatic primary EBV infection signature is characterized by high cell cycle 
gene expression, low type I IRG expression, and high IFNG expression. 
Figure S3: Gene set analysis can successfully segregate the EBV signature 
from other acute illnesses. 
Gene expression of the indicated genes was determined by qPCR on 11 symptomatic 
subjects.  Heat map indicated fold change from each subject’s own baseline.  K-
means clustering was performed on 8 blinded samples and three known EBV 
samples. A alysis was performed with three clusters and 10,000 runs. Three samples 
were obtained from subjects pres nti g with acute primary EBV infe tion. Fiv  
additional sa ples were collected from subjects presenting with other undefined acute 
illnesses. The symptomatic primary EBV infection signature is characterized by high 
cell cycle gene expression, low type I IRG expression, and high IFNG expression.  
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Response to EBV shares similarity to Dengue. From this comparison, we also 
observed that EBV shares little overall similarity to other acute infections with the 
exception of DENV. Almost 60% of the genes upregulated ≥ 3 by EBV, and 
nearly all of the downregulated genes were also similarly up/down regulated in a 
majority of DENV patients (Figure 2-4, purple and blue boxes). A possible pitfall 
to comparing disparate human infections and conditions is that sample timing 
may be different in infections with different incubation times. Nonetheless, the 
large group of “in common with DENV” genes was not upregulated at any time 
point even up to 28 days following YFV or Poly IC (Figure 2-7). Thus, 
upregulation of these genes seems peculiar to EBV and DENV.  
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Figure 2-7. Most EBV/DENV induced genes were not increased at any 
timepoint following YFV vaccination or Poly IC treatment. The genes shown 
were derived from analysis of EBV subjects (fold change ! 3 and met a statistical 
significance cutoff of p-value of " 0.05 with Bonferonni multiple-tests correction). 
Gene expression is shown in comparison to subjects with other viral infections 
(YFV and DENV) or subjects injected with Poly IC. Data is arranged as a 
hierarchical clustering of genes. Each column represents a single subject. 
Horizontal gray bars indicate that the gene of interest was not present in the 
analyzed dataset used for comparison. Vertical gray bars separate disease or 
time groupings. The color intensity represents fold changes in gene expression in 
comparison to either each subjects’ own healthy baseline (EBV, YFV and Poly 
IC) or in comparison to healthy controls (DENV). 
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Figure S4: Most EBV/DENV induced genes were not increased at any timepoint 
following YFV vaccination or Poly IC treatment. 
The genes shown were derived from analysis of EBV subjects (fold change ! 3 and met a 
statistical significance cutoff of p-value of " 0.05 with Bonferonni multiple-tests correction). 
Gene expression is shown in comparison to subjects with other viral infections (YFV and 
DENV) or subjects injected with Poly IC. Data is arrang d as a hierarc ical clusteri g of 
genes. Each column represents a single subject. Horizontal gray bars indicate that the 
gene of interest was not present in the analyzed dataset used for comparison. Vertical 
gray bars separate disease or time groupings. The color intensity represents fold changes 
in gene expression in comparison to either each subjects’ own healthy baseline (EBV, 
YFV and Poly IC) or in comparison to healthy controls (DENV).  
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Genes down-regulated after EBV. The heatmap in Figure 3 also identifies a 
discrete set of genes downregulated in acute EBV infection (Figure 2-4, blue box). 
Many of these genes are inflammatory or stress response genes expressed by 
monocytes, including IL1B, IL8, MIP2A, and OSM (Appendix Table A-3). The 
down-regulation of IL1B and IL8 was confirmed by real-time PCR in 70 
timepoints from 52 subjects (data not shown). This downregulation is particularly 
surprising for IL1B, which is considered a type I IRG and therefore one might 
expect it would be upregulated during viral infection. Indeed, IL1B was generally 
upregulated during antiviral responses, including subjects with Flu, HRV, and 
RSV, and subjects treated with Poly IC or SLE patients (blue asterisk in Figure 2-
4).  
 
EBV and DENV resemble inflammatory syndromes  
 Due to the surprising difference between the EBV/DENV signature and 
that observed in other acute viral infections, we theorized that perhaps the 
signature would more closely resemble that observed during inflammatory 
syndromes. To this end we examined microarray data obtained from subjects 
with familial hemophagocytic lymphohistiocytosis (FLH) (204) or subjects 
presenting with systemic onset juvenile arthritis (sJIA) who were later confirmed 
to have subclinical macrophage activation syndrome (MAS). (205) Both of these 
syndromes may be classified under the larger umbrella of hemophagocytic 
diseases, but are distinct in their origins. FLH is most commonly caused by 
mutations associated with degranulation genes, especially perforin (PRF1) and 
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the syntaxins. The genetic basis of MAS is less well understood but the vast 
majority of patients first present with sJIA. (206) Indeed, many of the gene 
changes shared between EBV and DENV were also found in patients with these 
inflammatory disorders (Figure 2-8). This suggests that the host defense to EBV 
and DENV more closely resembles uncontrolled inflammation that it does during 
other antiviral response. This would help explain the lack of similarity between 
the EBV response and what is observed in other acute viral infections or an IFN 
associate autoimmune disease.  
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Figure 2-8. EBV has high similarity to DENV and inflammatory syndromes. 
This heatmap compares the genes that change during primary EBV with DENV, 
and two syndromes: juvenile idiopathic arthritis with macrophage inflammatory 
syndrome (sJIA/MAS) and familial lymphocytic histiocytosis (FLH). The fold 
changes in gene expression are in comparison to either each subjects’ own 
healthy baseline (EBV) or healthy controls (DENV, sJIA/MAS and FLH). Genes 
shown had a fold change ≥ 3 in acute EBV and met a statistical significance 
cutoff of p-value of ≤0.05 with Bonferonni multiple-tests correction. 
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Type I and type II IFN response kinetics differ 
Although we cannot know precisely when subjects were infected with EBV, 
we were able to “stage” the subjects relative to the date of symptom onset. In the 
heatmaps shown, the subjects are ordered according to their symptom onset 
date. It is apparent that set B genes (IRGs) were upregulated in two of the pre-
symptomatic subjects, but the other major aspect of the signature was absent 
(Figure 2-7). To determine if this reflected temporally distinct aspects of the 
signature, we extended our analysis to multiple timepoints from a larger number 
of subjects. We employed the PCR array of 43 genes described above, 
representing genes in three main functional groups: Type I IRGs, type II IRGs, 
and cell cycle/metabolism. With this assay, we extended our analysis to include 
data from 70 different timepoints between -23 days and 20 days relative to 
symptom onset, comprising samples from 50 subjects. The trend from these 
analyses suggests that on average, type I IRG changes occur earlier during 
infection (including during the incubation period) than either type II IRG or cell 
cycle genes (Figure 2-9A).  
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Figure 2-9. Type I IRGs are slightly enriched before onset of symptoms, but 
some IRGs show no change. (A) Superarray analysis by qPCR was performed 
on 70 timepoints from 52 subjects to assess the time course of gene expression. 
Average fold changes for three groups of genes (Type I IRG, Type II IRG, and 
Cell Cycle as defined in Figure S1) were determined for samples collected within 
the indicated time blocks. Fold changes are compared with healthy baselines. 
Error bars show the standard deviation. All three gene groupings had a p-value 
<0.05 when evaluated by ANOVA.  (-20 days to -1 days N = 11; 0 days to 3 days 
N = 12; 4 days to 7 days N = 17; 8 days to 10 days N = 16). (B) The table shows 
the average fold change for nine select type I IRGs derived from microarray 
analysis for SLE, YFV, Flu, HRV, RSV, DENV, Poly IC, and EBV. (C) Heatmaps 
showing fold change as determined by qPCR for OAS1, MX1, and HERC5 at 
multiple timepoints in EBV infection (top panel) or in other situations (bottom 
panel).  
 
EBV fails to induce key interferon response genes 
While a type I interferon response clearly occurs during EBV infection, we 
were surprised to observe that MX1, which is a classic IFN induced GTP-binding 
protein, (207) was not upregulated in any of the primary EBV subjects. Upon 
further examination, we defined nine IRGs that were upregulated in all other viral 
infections, with Poly IC, and in SLE patients; but not in the EBV subjects (Figure 
2-9B). To determine if we may have missed an early spike in gene expression as 
suggested from the analysis above, we selected three of these MX1, OAS1, and 
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HERC5 and performed real-time PCR on 70 timepoints from 50 subjects. As 
expected, these genes were upregulated in every other acute infection data set 
examined and in SLE (Figure 2-9C bottom rows). However, none were 
upregulated more than two fold in any of the pre-symptom or post-symptom 
timepoints we examined (Figure 2-9C). Selective antagonism of specific IRGs or 
interferon signaling is common in viral infections. (208, 209) However, one would 
typically expect this to only be observed in virally infected cells (in our case, 
relatively rare circulating B cells). Instead the selective antagonism of IRGs we 
observed is occurring in the context of a systemic interferon response. Thus, we 
favor the hypothesis that EBV produces a soluble molecule that selectively 
antagonizes IRG gene expression in uninfected cells.  
 
The IRG signature of SLE is not similar to EBV 
EBV has been suggested to be involved in the pathogenesis of SLE. (210) 
A significantly higher proportion of SLE patients are infected with EBV than the 
general population (211, 212) and they have higher viral loads and antibody titers. 
(213, 214) Some SLE patients also have high IFN signatures. (202) Thus, it was 
hypothesized that the interferon response may be driven by EBV (210) and EBV 
derived nucleic acids could fuel type I IFN production via plasmacytoid dendritic 
cells. (215) We sought to investigate this link at the gene expression level. 
Patients with high IFN signatures (202) were compared with healthy controls 
using the same statistical criteria described for EBV above. Interestingly, we 
found that SLE had the least similarity to EBV as demonstrated by the low 
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Pearson r-value (Figure 2-10). Conversely, both Flu and Poly IC had high levels 
of correlation. In particular the nine IRGs that are selectively antagonized during 
EBV infection are strongly upregulated in SLE patients (Figure 2-9B). Thus, our 
data do not support the notion that EBV reactivation contributes to the interferon 
gene signature in SLE. 
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Figure 2-10. SLE has high similarity to influenza and Poly IC but not EBV or 
DENV. The heatmap lists the genes that are up/down regulated ≥ 2 fold in SLE 
patients compared with subjects with viral infections or who were injected with 
Poly IC. The fold changes in gene expression are in comparison to healthy 
controls (SLE and DENV) or to each subjects’ own healthy baseline (EBV, YFV, 
Flu, HRV, and RSV). Pearson r-values indicating degree of similarity between 
SLE and each of the other conditons are shown at the bottom of the heatmap. 
 
Type II IRG expression correlates with CD8 T cell expansion in primary EBV 
expression 
 Finally, we investigated whether or not there was a correlation between 
gene expression and severity of illness during acute infection. A hallmark of 
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infectious mononucleosis is the dramatic expansion of CD8 T cells. Indeed, both 
the total number of CD8 T cells/ml blood or the ratio of CD8 to CD4 T cells in the 
blood provided the best predictor of disease severity in a large prospective study. 
(14) Thus, using data from the qPCR superarray approach described above, we 
examined the correlation between gene expression and CD8 lymphocytosis. We 
found that expression of type I IRGs individually, or as a group, did not correlate 
strongly (Figure 2-11). This was true even when we limited the analysis to 
specific time windows where type I IRG gene expression was highest (data not 
shown). On the other hand, upregulation of type II IRG as a group did correlate 
positively (Figure 2-11). The upregulation of three individual genes correlated 
very significantly with CD8 lymphocytosis. These three: OASL, (Pearson r = 
0.6059, p < 0.0001) TYMS (r = 0.5019, p = 0.0006), and SLAMF8 (r = 0.6028, p 
< 0.0001), are all upregulated by IFNγ consistent with the known effects of IFNγ 
when given as therapy (216, 217). Interestingly, OASL in particular has been 
hypothesized to cause fatigue through antagonism of the thyroid receptor (218). 
Altogether these results reinforce the concept that many IM symptoms 
are immunopathologic, resulting from high levels of IFNγ produced by either 
innate or adaptive immune cells.  
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Figure 2-9. SLE has high similarity to influenza and Poly IC but not EBV or 
DENV. The heatmap lists the genes that are up/down regulated ≥ 2 fold in SLE 
patients compared with subjects with viral infections or who were injected with 
Poly IC. The fold changes in gene expression are in comparison to healthy 
controls (SLE and DENV) or to each subjects’ own healthy baseline (EBV, YFV, 
Flu, HRV, and RSV). Pearson r-values indicating degree of similarity between 
SLE and each of the other conditons are shown at the bottom of the heatmap. 
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Discussion 
This study provides the first gene expression profiling of a natural herpes 
virus infection in healthy human subjects. One notable aspect of the EBV gene 
expression profile was the striking upregulation of genes related to cell cycle and 
proliferation. While proliferation of cells is likely to be part of the immune 
response to any pathogenic virus, what is striking is the magnitude and duration 
of these gene expression changes, which allow them to be observed at the level 
of whole blood gene expression profiling. Most other viral infections did not 
display significant upregulation of these genes at any time point. The exception 
was DENV. Indeed the shared profile of EBV and DENV was also observed in 
hemophagocytic syndromes, emphasizing the exaggerated inflammatory 
response that ensues in these viral infections. Although other potentially 
interesting comparisons would be to DNA viruses, particularly CMV, which can 
cause IM, there are currently no data available on gene expression during 
primary infection in humans.  
In contrast to the readily apparent gene signature in acute infection, we 
were surprised to discover that there were no consistently detectable gene 
expression changes in human blood during latent infection, despite the sensitivity 
of our approach. EBV is known to persist in the B cell compartment, albeit at 
quite low levels (1-50 copies per million B cells). (219) The virus persists in a 
very “quiet” state, likely expressing viral RNAs (EBERs) but little or no viral 
protein products. (220) Nonetheless, immunosuppression can result in viral 
recrudescence with sometimes fatal consequences, (221, 222) thus EBV is 
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presumed to be under constant active immune surveillance. However, EBV is 
unlikely to be the only chronic viral infection present in our subjects. Up to a 
dozen chronic viral infections can be common in humans, including the related 
herpesvirus CMV (5) although it should be noted that the majority of our subjects 
(88%) were CMV negative and remained so throughout the study.  
Through comparison of the EBV signature to gene expression profiles of 
other acute viral infections in healthy individuals, we were able to identify the 
common and unique aspects of the response to EBV. While the response to all 
infections involved upregulation of IRGs, the response to EBV was notably 
lacking the upregulation of a subset of nine key IRGs. These particular genes are 
of interest as potential targets of viral antagonism. In addition we observed a 
striking downregulation of IL1B, which was surprising given that monocytes are 
activated and proliferating during acute EBV infection. Recent data suggested IL-
1β may be downregulated by type I IFN in human monocytic cells in vitro. (223) 
However, it is not clear why IL1B would be downregulated by IFN in EBV but 
upregulated by IFN in most other viral infections. Another possibility was 
suggested by a recent report, which showed that EBV encodes a microRNA 
(BART15) that targets the NLRP3 inflammasome, and exosome mediated 
secretion of this miRNA resulted in downregulation of IL-1β in bystander 
(uninfected) monocytes in vitro. (224) Intriguingly, IL1B was also down regulated 
in most DENV patients and in about half of subjects given the YFV vaccine 
(Figure 2-7). This disparate regulation may be interesting in the context of 
monopoeisis and an environment of high IFNγ production. In patients 
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administered G-CSF, immature monocytes entering the blood stream from the 
bone marrow bear surface bound IL-10. (225) In the presence of IL-10, 
monocytes that have become activated by IFNγ produce much less IL1B. (226) 
Furthermore, EBV encodes a viral IL-10 homologue (vIL-10) (227), suggesting 
another possible explanation for our observation. Further study will be required to 
determine the mechanism and significance of the profound IL1B downregulation. 
We hypothesize that the lack of upregulation of IL1B and key IRGs may allow 
this particular herpesvirus to avoid elicitation of adaptive immunity for many 
weeks, which may aid in establishing latency and provide an explanation for the 
long incubation period prior to symptoms. 
 
Materials and Methods 
Ethics statement 
All participants gave written informed consent and the University of Minnesota 
Institutional Review Board approved all protocols used.  
 
Design of prospective study  
We recruited 546 healthy undergraduate volunteers from the University of 
Minnesota residence halls in 2006 and 2007 as recently described. (194) EBV 
naïve subjects were identified as those lacking IgG antibodies against EBV viral 
capsid antigen (EBV VCA IgG) and EBV nuclear antigen 1 (EBNA1). Of the 202 
eligible EBV-naïve subjects, 143 (71%) were enrolled in the prospective study. 
For enrolled participants, blood and oral washings were collected at least every 8 
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weeks during the academic year in addition to an electronic monitoring journal to 
track development of symptoms between visits. Subjects with symptoms 
consistent with acute primary EBV infection were asked to come to the clinical 
virology research clinic for both a physical exam and laboratory-confirmation of 
primary EBV infection via Monospot, EBV serology, and viral titer in the oral 
cavity or blood. 66 subjects experienced primary infection (46%), of which only 6 
were asymptomatic. (194) Primary EBV infection was defined as a positive EBV 
antibody test and the presence of EBV DNA in the blood and/or oral 
compartment of a subject who was previously negative for both EBV antibodies 
and EBV DNA. All participants continued pre-scheduled follow-up visits after 
seroconversion.  
 
Samples collection and handling 
Peripheral blood samples were obtained from subjects via venipuncture and 
collected in 10ml purple-top EDTA Vacutainer® tubes (Fisher Scientific). 200µl of 
blood was used for DNA extraction and HLA typing. Blood Peripheral blood 
mononuclear cells (PBMCs) were isolated by Accuspin™ System-Histopaque®-
1077 (Sigma-Aldrich) density gradient centrifugation per manufacturer’s 
instructions. PBMC counts were recorded post-ficoll purification of whole blood 
during each collection and stored as detailed below. Once pelleted, cells were 
frozen in 1 x 107 cells/ml aliquots in a cryopreservative solution containing 90% 
FBS and 10% dimethysulfoxide (DMSO) (Sigma-Aldrich). Samples were allowed 
to slowly freeze at -80°C overnight and then transferred to liquid nitrogen for 
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storage until needed. Cells were rapidly thawed in a 37°C water bath, diluted to 
10ml in RPNK media supplemented with 50U/ml benzonase (Novagen) (RPNK 
media: RPMI 1640 (Cellgro) supplemented with 10% FBS (Atlanta Biologicals), 
2% Penicillin - Streptomycin (5000U/ml, 5000µg/ml respectively, GIBCO, 
Invitrogen) and 1% L-glutamine (29.2mg/ml, GIBCO)). Cells were then counted 
using a hemocytometer and divided into separate fractions for flow cytometry or 
RNA processing. 
 
RNA extraction 
For each sample, 1-2 x 106 PMBCs were used for each RNA extraction. Cells 
were first homogenized using QIAshredder columns (Qiagen) per the 
manufacturer’s instructions. RNA was then extracted using RNeasy kit (Qiagen) 
with on column DNase step (Qiagen) per the manufacturer’s instructions. RNA 
was then quantified using a Nanodrop 2000/2000c spectrophotometer (Thermo 
Scientific) and kept frozen at -80°C. 
 
Microarray 
200ng of RNA per sample was amplified for microarray analysis using the 
Illumina TotalPrep RNA Amplification Kit (Ambion) per the manufacturer’s 
instructions. Tagged transcripts were then sent to the microarray facility of the 
BioMedical Genomics Center at the University of Minnesota for hybridization to 
an Illumina Sentrix BeadChip HumanRef-8 v3. Preinfection and latent samples 
were hybridized to Illumina HumanHT-12 v4 Expression Beadchips.  
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Microarray analysis and heatmap generation 
Raw data from (198-200, 202-205) were obtained from the GEO database and 
analyzed independently as described. Signal values from all microarrays were 
imported into the microarray analysis program GeneSpring (Agilent). Signal 
values were normalized by percentile and filtered to eliminate noise from the data. 
Fold changes were calculated as the difference between acute infection samples 
and baseline (in the event that the subjects had baselines) or healthy controls 
(for clinical studies with no available baselines). Studies with before and after 
samples were subjected to a paired t-test with Bonferonni multiple tests 
correction. Studies which used healthy controls were subjected to an unpaired 
unequal variance t-test (Welch) with Bonferonni multiple tests correction. Log2 
transformed fold changes were exported from GeneSpring into a *.txt file. These 
values were imported into the open source program Cluster 3.0, (228) which 
clustered the genes hierarchically using a Pearson non-averaged correlation and 
average linkage. Heatmaps were then visualized using the program Java 
Treeview. (229) 
 
Ingenuity Pathway Analysis  
Pathway analysis was performed using Ingenuity Pathway Analysis (IPA) 
software (Ingenuity System). Gene sets were screened to limit the number of 
genes utilized for analysis. For the acute gene set, the 464 significantly changed 
genes previously described were used. 53 genes with potential long-term 
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changes were used from the latent analysis. Log2 transformed fold changes for 
all relevant genes were imported into the software using their Illumina probe 
identifiers and were then associated with their appropriate gene symbol by IPA. 
The software then used these genes and their fold changes to determine which 
gene sets had statistically significant importance in each of the cases. Canonical 
pathways were assigned based on the number of genes present in our geneset 
for each pathway, the level at which these genes were up or down regulated, and 
the likelihood these trends would occur by chance by using the multiple test 
correction Fisher’s exact test. Results are reported in this work as the Benjamini-
Hochberg p-value or ratio. 
 
Gene Set Enrichment Analysis 
Gene Set Enrichment Analysis (GSEA) was performed on whole chip acute and 
latent infection microarray data using GSEA software (Broad Institute). Analysis 
was performed per Broad Institute instructions.  
 
Fluorescence activated cell sorting 
Frozen PBMCs from baseline and acute IM timepoints from 4 subjects were 
thawed and stained to be sorted into four different subsets: CD8 T cells (CD3+, 
CD56-, CD8+), NK cells (CD56+, CD3-), B cells (CD19+, CD20+), and 
monocytes (CD14/CD16). Subsets were sorted into 1.5 ml tubes pre-coated with 
media using a FACS Aria under BSL-2 sorting conditions. Cells were washed 
with PBS and RNA was extracted as described above. 
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cDNA synthesis and PCR analysis using SuperArray 
100ng of RNA was used with the SuperScript III Platinum Two-Step qRT-PCR Kit 
(Invitrogen) to generate cDNA. Samples were then stored at -20°C. 43 genes 
were selected for analysis by PCR from a larger list of changed genes in IM 
subjects and other acute viral infections that comprised relevant functional 
groupings as assessed by IPA. 384-well SuperArray plates pre-coated with 
primers for the desired 43 genes plus 5 controls were obtained as a custom order 
from SABiosciences. 10 µL of cDNA per subject was used with RT2 Real-time 
SYBR green/Rox PCR master mix (SABiosciences) for qRT-PCR analysis. 
Products were detected using an ABI Prism 7900HT Sequence Detection 
System (Applied Biosystems). The genes ACTB, B2M, and RPL13A were used 
as housekeeping genes during the calculation of fold changes as they had 
previously been shown not to change significantly during acute EBV infection 
(data not shown). Fold changes were calculated as: 2^(Δ Acute Housekeeping 
Control – Baseline Housekeeping Control)/2^(Δ Acute Gene of Interest – 
Baseline Gene of Interest).  
 
Blinded study and K-means clustering 
Subject samples for the blinded gene signature study were chosen by H.H.B Jr 
and RNA extraction was performed by O.A.O to ensure S.K.D was blinded to 
sample identity. cDNA synthesis, qRT-PCR and analysis were performed by 
S.K.D. Sample cycle thresholds were imported into Cluster 3.0 as a text file and 
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a K-means clustering was performed on the samples with 3 groupings and 
10,000 iterations to provide a sufficient number of successful solutions from the 
algorithm.  
 
Statistical analysis 
Except for where Genespring (Agilent) or IPA (Ingenuity Systems) was used, 
most other statistical analysis was performed using Prism software (Graphpad). 
MedCalc (MedCalc Software) was used for comparison of Pearson correlation 
coefficients. Comparisons between groups were performed with either an 
unpaired two-tailed t-test or a one-way ANOVA with a p-value less that 0.05 as 
the cutoff for statistical significance. Pearson correlation coefficients were 
generated with Prism by comparing pairs of relevant groupings. 
 
Accession numbers 
Gene expression data is available from the Gene Expression Omnibus. The data 
are part of superseries GSE45924 composed of two subseries, GSE45918 and 
GSE45919.  
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Chapter 3 
The incubation period of primary Epstein-Barr virus infection: viral 
dynamics and immunologic events 
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Abstract 
Epstein-Barr virus (EBV) is a human herpesvirus that causes acute infectious 
mononucleosis and is associated with cancer and autoimmune disease. While 
many studies have been performed examining acute disease in adults following 
primary infection, little is known about the virological and immunological events 
during EBV’s lengthy 6 week incubation period owing to the challenge of 
collecting samples from this stage of infection. We conducted a prospective study 
in college students with special emphasis on frequent screening to capture blood 
and saliva samples during the incubation period. Here we describe the viral 
dissemination and immune response in the 6 weeks prior to onset of acute 
infectious mononucleosis symptoms. While virus is presumed to be present in 
the oral cavity from time of transmission, we did not detect viral genomes in the 
oral wash until one week before symptom onset, at which time virus was present 
in high copy numbers, suggesting loss of initial viral replication control. In 
contrast, using a sensitive nested PCR method, we detected virus at low levels in 
blood about 3 weeks before symptoms. However, high levels of EBV in the blood 
were only observed close to symptom onset –coincident with or just after 
increased virus in the oral cavity. The early presence of virus in the blood, even 
at low levels, correlated with a striking decrease in the number of circulating 
plasmacytoid dendritic cells well before symptom onset, which remained 
depressed throughout convalescence. On the other hand, natural killer cells 
expanded only after symptom onset. Likewise, CD4+ Foxp3+ regulatory T cells 
decreased two fold, but only after symptom onset. We observed no substantial 
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virus specific CD8 T cell expansion during the incubation period, although 
polyclonal CD8 activation was detected in concert with virus increasing in the 
blood and oral cavity, possibly due to a systemic type I interferon response. This 
study provides the first description of events occurring in vivo during the 
incubation period of natural EBV infection in humans, and definitive data upon 
which to formulate theories of viral control and disease pathogenesis. 
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Introduction 
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus. As with all 
herpesviruses, EBV causes lifelong infection in its host. Infection is associated 
with autoimmune diseases (57, 189) and is known to cause several types of 
cancer, representing 1% of the worldwide cancer burden (187). Primary infection 
in children is either asymptomatic or causes mild symptoms not readily 
associated with EBV. In adolescents and young adults, however, EBV is most 
commonly recognized as the etiologic agent of acute infectious mononucleosis 
(230). The virus is chiefly transmitted from person to person in saliva, although it 
can be acquired from blood transfusions or from receipt of allogeneic donor cells 
or tissue. There is currently no vaccine or effective treatment for infectious 
mononucleosis or other EBV related diseases. Because EBV infection is limited 
to primates, there are no small animal models of infection except humanized 
mice (231). Neither humanized mice nor mice infected with the related gamma 
herpes virus MHV68 exhibit true infectious mononucleosis. Therefore a detailed 
and accurate understanding of primary infection in humans is critical for 
developing therapeutic tools to treat EBV related diseases.  
Abundant data are available on infectious mononucleosis in humans, 
especially the most severe cases, as subjects are typically seen in clinic. Indeed, 
the antibody and cell mediated adaptive immune response to the virus, and how 
it wanes and changes after infectious mononucleosis presents is well established 
(106). However a particular knowledge gap exists regarding the events that occur 
between transmission and symptom onset—the incubation period—which is 
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unusually long, about six weeks (13, 16). In comparison, most other acute viral 
infections have incubation periods ranging from less than a day to a week (232). 
Thus in particular, we lack knowledge about initial infection events and the innate 
immune response to EBV in humans; although these are presumed to be critical 
as EBV has a multitude of innate immune evasion mechanisms (233, 234).  
From in vitro studies, we know that EBV efficiently infects B cells through 
binding of viral gp350 and gp42 proteins to the B cell surface molecules CD21 
and HLA Class II, respectively (30). However, EBV can also infect oral epithelial 
cells, albeit much less efficiently (23). It is unknown which cells are initially 
infected in the oral cavity during natural infection. One possibility is that the virus 
infects and replicates in oral epithelial cells early during primary infection; but 
infectious mononucleosis does not occur until B cells are later infected in the 
tonsils, and virus disseminates to the blood. The virally encoded LMP1 and 
LMP2 proteins are known to drive infected B cells to differentiate by acting as 
functional homologues of CD40 and the BCR respectively, and this also triggers 
migration from tonsils to the blood (235). Another model proposes that both cell 
types are infected early in the oral cavity, and that cycles of infection and 
reactivation must occur during the incubation period to ultimately produce high 
levels of infected B cells in circulation, which drives infectious mononucleosis 
(25). Alternatively, a third model is that B cells may be initially infected in tonsils 
where they vertically transmit virus at low levels (236). Infection would be limited 
to B cells in the nasopharyngeal secondary lymphoid tissue until some stochastic 
event caused reactivation of the virus, spreading virus to epithelial cells and 
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resulting in an acute increase in viral load, occurring weeks after initial infection. 
The dynamics of tissue tropism of EBV are interesting in this context, as the virus 
produced by epithelial cells is particularly efficient at infecting B cells, and vice 
versa (23). Each of these three models make distinct predictions about the 
relative levels of virus in the oral cavity versus blood during the incubation period, 
and would suggest different strategies to combat infection therapeutically, as 
antiviral compounds only target actively replicating virus.  
Although it is critical to understand the viral and immunological events that 
occur during the incubation period, it is challenging to obtain both samples and 
comprehensive clinical data during this period. To address this need, we enrolled 
undergraduate volunteers who were naïve to EBV and monitored them routinely 
for natural infection, capturing timepoints within the incubation period by chance. 
Through frequent sampling, we were able to obtain 48 incubational samples from 
40 young adult study participants. We sought to detect and quantify virus in the 
blood and oral cavity, with particular attention to when virus disseminates from 
nasopharyngeal tissue to the periphery. In addition, innate and adaptive immune 
responses during this period were examined, with particular emphasis on natural 
killer (NK) cells, plasmacytoid dendrtitic cells (pDC), CD8 T cells, and Foxp3+ T 
regulatory (Treg) cells. Surprisingly, during the incubation period, virus was 
detected at low levels in peripheral blood prior to detection in the oral cavity. A 
dramatic reduction in blood pDC numbers and a type I interferon response were 
observed roughly coincident with viral increases in the blood. In contrast, the 
dramatic increase in CD8 T cell numbers characteristic of AIM, the distinctive 
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type II interferon/cell cycle gene expression signature of AIM, and changes in NK 
cell phenotype and Treg cell numbers previously reported to occur during 
infectious mononucleosis were not observed until symptom onset. We discuss 
possible mechanisms to explain these changes and implications for the treatment 
of EBV related diseases.  
 
Results  
Study design 
We previously described a prospective study of primary EBV infection in 
66 undergraduates at the University of Minnesota (14), 59 of whom were 
symptomatic. As an extension of this study, we enrolled a new prospective cohort 
with the specific aim of more frequent sampling in order to serendipitously 
capture more samples from the incubation period of primary EBV infection. From 
both cohorts combined, a total of 48 blood and oral wash samples from 40 
subjects were obtained during the historically defined incubation period (42 days). 
These samples were the focus of this study. Since the exact date of infection with 
EBV is undefinable in a study of natural infection, we designated the date of 
symptom onset as day “zero.”  
 
Viral dissemination into circulation occurred before large quantities of 
virus were detected in the oral cavity 
EBV is transmitted through salivary exchange in young adults and 
infection is established in the oral cavity, both in squamous epithelial tissue and 
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lymphocytes of the Waldeyer’s ring (35). Very little is known, however, about 
when and how EBV egresses from tonsillar tissue into the peripheral blood. In 
order to examine dissemination during the 6 week incubation period more closely 
we tested for the presence of viral genomes by both quantitative PCR (qPCR) 
and by a highly sensitive nested PCR. The nested PCR assay gave a much more 
sensitive but non-quantitative readout of viral presence, whereas the limit of 
detection for the quantitative PCR assay was 200 copies of EBV per milliliter of 
whole blood or 40 copies of virus per millilter of oral wash. Surprisingly, virus was 
not detected in the oral cavity by either method, until approximately a week prior 
to symptom onset, at which point large amounts of viral genomes were detected 
(Figure 3-1A). These data are expressed at a per subject level as “time to first 
response” in Figure 3-1C. Virus was detected in both cells from the oral wash as 
well as supernatant, suggesting that virus persists in the oral cavity at very low 
levels for the first 4-5 weeks after transmission, and then exhibits an explosive 
pattern of replication.  
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Figure 3-1. Virus detection during the incubation period. Quantitative viral 
load was determined by qPCR using DNA from oral wash cell pellets (A) or blood 
(B). Data are expressed as Log10 viral genome copies/ml of sample. The dashed 
gray line represents the limit of detection. (C) and (D) show the time to the first 
positive measurement for each subject for virus detected in the blood (D) by non-
quantitative nested PCR (filled squares) or qPCR (filled inverted triangles), or in 
the oral cavity (C) by nested or qPCR (same results were obtained with both 
assays) (open circles). (E) In sequential samples from the incubation period, 
subjects were scored for which compartment virus was first detected in: blood (by 
nested PCR), blood (by qPCR), oral, or a simultaneous positive in both 
compartments. (F) Shows an inset comparing blood and oral cavity for the time 
period close to symptom onset. The results for twenty-six subjects who had a 
sample collected within the first two weeks of symptom onset are shown. 
 
In contrast, virus was detected in peripheral blood as early as 22 days 
prior to symptom onset, but was only detected via the more sensitive nested 
PCR assay at this early stage (Figure 3-1 B and D). In fact, 10 subjects showed 
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virus detection in the blood before the oral cavity when consecutive timepoints 
were evaluated (Figure 3-1E). It should be noted that we were able to obtain 
substantially more DNA from blood cells than from oral wash cells, which could 
explain why low levels of virus were not detected early in the oral cavity. 
Nonetheless, we detected dramatically higher viral loads in the oral wash at the 
time of symptom onset (Figure 3-1A), suggesting efficient viral detection in oral 
samples. Virus detection in the blood using the less sensitive qPCR assay was 
delayed by at least a week (Figure 3-1F), and viral genomes >200 copies/ml 
were not found in any individuals until on or after timepoints where high viral 
loads were detected in the oral cavity (Figure 3-1E). These data provide the first 
description of EBV viral dynamics during the incubation period of natural infection 
in humans, and suggest a scenario where viral replication is self-limiting in the 
oral cavity for many weeks. Dissemination to the blood occurs during this “quiet 
period”. Closer to the time of symptom onset, virus replicates rapidly in the oral 
cavity, and subsequently high viral loads are detected in the blood.  
 
Gene expression changes in peripheral blood are apparent 1-2 weeks prior 
to symptom onset 
Previous work from our group revealed that distinct gene expression 
signatures were present in peripheral blood mononuclear cells early versus late 
after primary EBV infection (87). We sought to expand this dataset by examining 
the additional incubational samples obtained from our most recent cohort. 
Samples were evaluated by PCR SuperArray consisting of 43 genes 
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representative of gene changes initially observed by microarray (87). Heirarchical 
clustering revealed three distinct patterns from incubational samples (Figure 3-2). 
Subjects exhibited either no change, a type I interferon (IFN) signature, or a type 
II IFN/cell cycle signature. These signatures clustered temporally, segregating 
into these approximate time frames: (i) no change seen from -42 to -7 days prior 
symptom onset, (ii) a type 1 IFN signature from -15 to -3 days, and (iii) the 
distinctive type II IFN/cell cycle signature associated with infectious 
mononucleosis within days of symptom onset. Notably, the type I IFN signature 
was present when virus was detected only by nested PCR (low viral loads) in 3 
out of 4 subjects, although 7 subjects showed no interferon response despite the 
presence of virus in blood by nested PCR.  
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Figure 3-2. Gene expression signatures during the incubation period 
showed distinct kinetic patterns. 43 EBV infection signature genes were 
measured in total PBMC RNA. Functional categorization of the genes is shown at 
left. Fold change (FC) in expression was calculated compared to pre-infection 
samples. Heirarchical clustering (above) showed three distinct groupings: no 
signature (red), type I IFN (blue), and type II IFN/cell cycle (green). Subject 
numbers and sample collection date are indicated at top. The presence of virus 
by nested (lo) or qPCR (hi) is noted below, along with the range of sample days 
(relative to symptom onset) that each signature was observed in.  
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Plasmacytoid dendritic cell numbers in the circulation decrease as virus 
first becomes detectable 
Plasmacytoid dendritic cells (pDC) are major producers of type I IFN. 
Although a robust type I IFN response was observed during the incubation period 
in some study participants, the gene expression signature was relatively transient. 
Khanna’s group recently found pDC numbers to be reduced in acute IM patients 
(237). Thus, we thus sought to examine pDC numbers during the incubation 
period. pDC were identified as BDCA-2+ CD123+ cells amongst non-lymphoid 
cells (CD3, CD20, CD56 and CD14 negative) and were HLA-DR+ and CD11c- 
(not shown). As an example, flow plots are shown for 6 timepoints from subject 
5524 (Figure 3-3A and B) Analysis of pDC from all subjects during the incubation 
period revealed a remarkable decline during the ten-day period leading up to 
symptom onset (Figure 3-3C and E). A slight decline was observable before that, 
but was not statistically significant. In contrast, conventional myeloid derived DC 
(cDC), identified as HLA-DR+ CD11c+ amongst non-lymphoid cells, were not 
significantly increased or decreased during either the incubation period or the 
early phase of infectious mononucleosis (Figure 3-3D). The loss of pDC in 
circulation was strongly correlated with the presence of virus in peripheral blood 
(Figure 3-3F). Interestingly, the reduction in pDC was as profound at timepoints 
where only low levels of virus were detected as when high levels of virus were 
detected (Figure 3-3F), and there was no significant correlation between the 
number of viral genomes present and the extent of pDC reduction.  
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Figure 3-3. Plasmacytoid DC declined in the circulation during the 
incubation period and remained depressed through convalescence. (A) 
Representative flow cytometry plots of pDC frequencies amongst non-lymphoid 
cells (CD3, CD56, CD14, CD20 negative) from samples collected at multiple 
timepoints for one subject (5524).  (B) The percentage of pDC from 5524 over 
time. (C) Frequencies of pDC over time are shown for all subjects. (D) 
Frequencies of conventional DC (cDC) (CD11c+, HLA-DR+ cells) are shown over 
time for all subjects. (E) Numbers of pDC per mL of whole blood are shown for all 
subjects. (F) shows the percentage of pDC in samples where virus was detected 
in the blood by nested PCR (Blood lo) or qPCR (Blood hi). Statistical analysis 
was performed using a one-way ANOVA with multiple test comparison. Light pink 
symbols indicate a significant difference (p<0.05) compared to pre-infection; 
darker pink symbols (p<0.001); red symbols (p<0.0001). Gray symbols indicate 
no statistical difference. 
 
Natural killer cell ratios and phenotype were not affected until onset of AIM 
The importance of NK cells in EBV infection has become increasingly 
apparent in recent years (238). Changes in NK cell phenotype during infectious 
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mononucleosis were reported previously, and included a loss of CD56bright 
“immature” NK cells and a corresponding increase in CD56dim “mature” NK cells 
(239). We also observed a reduction in CD56bright NK cells in this cohort; however, 
unlike pDC changes, NK cell changes were not apparent until symptom onset 
(Figure 3-4A). We further examined a specific CD56dim NKG2A+ KIR- cell subset 
reported to be expanded during infectious mononucleosis as a consequence of 
virus-induced proliferation (121). We observed a similar expansion in our cohort, 
but it likewise was not detected until symptom onset, and remained elevated for 
at least 50 days (Figure 3-4B). 
 
Figure 3-4. NKG2A+ NK cells were expanded during AIM, but not during the 
incubation period. (A) Percentage of NK cells that are CD56bright (immature) 
decreases during the first 50 days after symptom onset. (B) The percentage of 
NK cells that are CD56dim NKG2A+ KIR- increases, and remains elevated. 
Statistics were performed using a one-way ANOVA with multiple test comparison. 
Pink symbols indicate a significant difference (p<0.05) compared to pre-infection. 
Red symbols indicate a significant difference (p<0.0001) compared to pre-
infection. Gray symbols indicate no statistical difference. 
 
Polyclonal CD8 T cell activation was detected during the incubation period, 
but virus specific CD8 T cell expansion was not 
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CD8 T cells provide vital immune control of EBV (106), and although their 
expansion during infectious mononucleosis has been well documented, it is not 
known when they first become activated during primary infection. Using 
peptide:MHC I tetramers, we detected no EBV specific CD8 T cell expansion 
(tetramer binding cells above .05% of CD8 T cells) until timepoints near the onset 
of symptoms (Figure 3-5A and 3-6). Similarly, upregulation of CD11a and 
downregulation of CD45RA on tetramer binding T cells, indicating antigen 
experience, were not seen until symptom onset. The expansion of EBV specific T 
cells was tightly concordant with total CD8 T cell expansion, as reflected by an 
increased CD8:CD4 ratio (Figure 3-5 A and C). Interestingly we detected 
upregulation of CD38 and granzyme B on total polyclonal CD8 T cells earlier, 
during the incubation period (Figure 3-5A and B, and 3-6). These features of 
polyclonal activation correspond kinetically to when a type I IFN response was 
most strongly represented (Figure 3-2).  
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Figure 3-5. CD8 T cell activation occurred during the incubation period, 
although not an EBV specific response. (A), Time to first response for three 
distinct immune parameters is shown: CD38 upregulation on total CD8+ T cells 
(filled squares), an increased CD8 to CD4 T cell ratio (open diamonds), or the 
presence of EBV tetramer binding CD8+ T cells above background (0.4%) (filled 
circles). (B) Frequency of CD8+ T cells expressing CD38 over time. (C) Ratio of 
CD8+ to CD4+ T cells over time. Statistics were performed using a one-way 
ANOVA with multiple test comparison. Pink symbols indicate a significant 
difference (p<0.05) compared to pre-infection. Red symbols indicate a significant 
difference (p<0.0001) compared to pre-infection. Gray symbols indicate no 
statistical difference. 
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Figure 3-6. Representative flow cytometry plots of T cell analysis. The top 
two rows show binding of EBV tetramers (pools of 7 lytic/latent antigen/HLA 
tetramers prepared with APC-streptavidin) to CD8+ T cells (top row) or CD4+ T 
cells (control, second row) at the indicated time points relative to symptom onset 
in subject 7001. The 3rd and 5th rows show plots gated on tetramer+ CD8+ T cells, 
showing expression of memory markers (CD45RA and CD11a, 3rd row) or 
activation markers (CD38 and granzyme B, 5th row). The 4th and 6th rows show 
expression of memory (4th row) or activation markers (6th row) on total CD8+ T 
cells.  
 
Foxp3+ CD4 T cell numbers in the circulation decrease after presentation 
with acute infectious mononucleosis 
Foxp3+ CD25+ Treg cells, are important for the maintenance of self-
tolerance and dampening chronic inflammation. A reduction in the number of 
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circulating CD25hi CD4+ T cells was previously reported in infectious 
mononucleosis patients (240), but it was unknown when these changes began to 
manifest and how long they persisted through convalescence. Analysis of 
individual subjects over time in our study corroborated a decrease in Treg cells at 
the onset of infectious mononucleosis (Figure 3-7 A and B, shown for a 
representative subject). In all subjects, Treg cells were significantly decreased 
only during the first ten days of infectious mononucleosis (Figure 3-7B). The 
overall number of CD4+ T cells, in contrast, was unchanged (Figure 3-7C). 
Although the fate of blood Treg cells during infectious mononucleosis is unknown 
(e.g. whether they trafficked to tissues or died), previously reported histology of 
infectious mononucleosis tonsils would argue against local infiltration into tonsils, 
although the n of this study was very small (240).  
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Figure 3-7. CD4+ Foxp3+ T cells transiently decline in the circulation at 
symptom onset during acute infectious mononucleosis. (A) Frequency of 
Foxp3+CD25+ cells amongst total CD4+ T cells data plotted over time for a 
representative individual (subject 7112). (B) Normalized frequency of Foxp3+ 
CD4 T cells over time in all subjects. Foxp3+ frequencies were normalized to 
each subject’s pre-infection baseline due to substantial variation in this 
population between individuals. (C) Number of CD4+ T cells per mL of whole 
blood over time. Statistics were performed using a one-way ANOVA with multiple 
test comparison. Gray values are not statistically different. Red value p<0.0001 
compared to pre. 
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Discussion 
Our findings have important implications regarding how EBV infection 
progresses through natural routes in its native host. Despite an oral transmission 
mode, virus was not detected in the oral cavity in appreciable quantities until 
subjects had presumably been infected five to six weeks. The lack of detectable 
virus in oral wash argues against substantial lytic replication within squamous 
epithelial cells early during infection. Rather, it is consistent with the idea that B 
cells are a major cell type initially infected in the nasopharyngeum. EBV 
efficiently infects B cells, particularly when virus is derived from epithelial sources, 
which it likely would be during transmission, since virus produced by epithelial 
cells packages more gp42 into virions than virus produced by B cells (30). 
Infected B cells are known to divide and differentiate, replicating the viral genome 
as an episome along with cellular division (35). This “vertical” replication would 
be expected to expand viral load relatively slowly, compared to active viral 
replication in lytically infected cells. Starting approximately 1 week before 
symptom onset, virus became detectable at high copy number in the oral wash. It 
is unclear what event precipitates this sharp increase, but it was not gradual like 
the decline in viral loads in the oral cavity during latency. It has been postulated 
that undefined signals may trigger viral reactivation in latently infected B cells 
(220), which could then lead to high local production of virus and large-scale 
infection of epithelial cells.  
Interestingly, our data would also suggest that infected B cells begin to 
disseminate into circulation prior to events that precipitate large scale viral 
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production in the oral cavity. Notably, in 10 subjects we detected low levels of 
virus in peripheral blood at timepoints prior to detection in the oral cavity. 
Furthermore, in 7 subjects with low virus present in the blood, there was no type I 
IFN response detected. This is consistent with the idea that virus is disseminated 
into circulation via latently infected memory B cells (38) where it goes undetected 
by the innate immune system. Indeed, infected B cells were shown to transition 
into a “latency 0” stage that closely resembles resting memory B cells, with 
altered trafficking patterns (241).  
Another point that emerges clearly from these data, is that systemic innate 
and adaptive immune responses do not occur until viral loads rise relatively late 
in the incubation period, either in the oral cavity or the blood. The earliest 
responses detected were a type I interferon response (Fig 2) and upregulation of 
CD38 on total CD8 T cells (Fig 5), which occurred during the 10 days prior to 
symptom onset. These two observations may be related, as it was previously 
shown that type I IFN can upregulate granzyme B in CD8 T cells, independent of 
activation through the antigen receptor (242). Indeed, the proportion of CD8 T 
cells that upregulated CD38 and Granzyme B (>80% in some individuals) at 
these early time points is too high to be explained by T cells recognizing virus 
through their antigen receptor, as clonal expansion had not been detected at 
these time points. Of note is the fact the type I IFN response was relatively 
transient and not associated with symptoms in any of the study subjects.  
An adaptive immune response followed these early events, with 
expansion of virus specific CD8 T cells, and increased CD8:CD4 ratios rising in 
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all subjects in the first 10 days following symptom onset. IgM responses to EBV 
viral capsid antigen were also detected in this time frame. As previously reported, 
IgG responses to VCA developed subsequent to IgM, and IgG responses to 
EBNA-1 were not maximal until after 3 months. Foxp3+ T regulatory cells were 
reduced during symptomatic IM as reported previously (240). A similar reduction 
is observed in various infections in mice (243, 244), where reduction of effector 
cell IL-2 in the face of inflammatory cytokines was suggested to be the 
mechanism (245). Too little Treg activity can result in immunopathology (245), 
and we did observe an inverse correlation between Treg percentages during 
acute infection and disease severity (Spearman r= 0.4871, p=0.0251) although 
whether this is causative remains to be explored in EBV.  
 Curiously, blood NK responses were observed only after symptom onset 
and not earlier, although NK cells are thought to function early in infections. This 
result may not be entirely unexpected, as NK cells respond preferentially to 
lytically rather than latently infected cells (115), and our results suggest that 
latently infected cells are introduced into circulation prior to lytically infected cells. 
NK cells are thought to play a protective role in infectious mononucleosis as 
evidenced by NK cell depletion in humanized mice infected with EBV, which 
resulted in higher levels of blood viremia (115). It is possible that NK cells in the 
tonsil play a critical role in humans, limiting viral spread amongst epithelial cells. 
Furthermore, NK cells have been hypothesized to play a role in the age 
dependence of symptomatic primary EBV infection. For example, newborns were 
reported to have more than twice as many circulating CD56dim NKG2A+ KIR- NK 
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cells than adolescents (121), which could explain why children experience less 
EBV associated morbidity in comparison with adolescents and young adults. 
However, it was recently reported that infants with asymptomic primary EBV 
infection have blood viral loads as high as adults with infectious mononucleosis 
(71), which is not consistent with a model of better NK control of viremia in 
infants. By closely observing the viral and immune dynamics during natural 
infection, we offer a new hypothesis on infectious mononucleosis pathogenesis, 
which proposes that explosive viral replication in the oral cavity creates a 
situation of exaggerated CD8 T cell response that characterizes disease. It may 
be that children experience less infectious mononucleosis than adults despite 
ultimately achieving equally high levels of infected B cells in the blood because 
infection in the oral cavity was not initially held in check allowing the adaptive 
immune response to develop by the time blood levels of virus increased. Indeed, 
memory CD8+ T cells specific for the virus, were observed in asymptomatic 
infants concurrent with high viral loads (71). Ironically, it may be heightened oral 
innate immune surveillance in adolescents and adults, compared with children, 
that puts them at risk for infectious mononucleosis. 
 A final point of interest in our study was that circulating pDC percentages 
and numbers were significantly diminished during the viral incubation period. The 
pDC decrease initiated during the same period as a type I IFN response and 
polyclonal CD8 T cell activation were observed—the 10 days prior to symptom 
onset. Unlike the type I IFN response, which was transient, the pDC reduction 
was sustained for up to 50 days. The reduction was also observed at all 
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timepoints (except one) that showed the presence of virus, even low levels of 
virus, and even when a type I IFN response was not present. From this we 
conclude that viral infection or viral products were responsible for the pDC 
reduction, but it was unlikely to be mediated by the host’s type I IFN response. 
This reduction could be related to the dynamics of pDC activation. Evidence in 
the literature suggests that pDC can mature or leave the circulation into tissues 
or secondary lymphoid organs during infections (246). Upon activation, pDC 
enter a maturation program that can result in progression of pDC into cDC (247); 
however, we did not see a corresponding increase in cDC percentages. 
Alternatively, reduction of circulating pDC numbers may be related to the BamHI-
A rightward frame 1 (BARF1) protein secreted by EBV during lytic replication 
(248). BARF1 enhances viral replication and persistence in part by binding to and 
inhibiting the signaling of colony stimulating factor (M-CSF) (176, 179) an 
important factor for the survival and maintenance of pDC (178). It would be 
interesting to determine if primates infected with a BARF-1 deficient form of 
lymphocryptovirus show pDC reductions or not. The functional consequences of 
pDC loss from the blood during primary infection remain to be explored.  
 In summary, we report several novel findings about the viral and immune 
dynamics during the lengthy incubation period of primary EBV infection. These 
include relatively early dissemination of virus into circulation in a form that does 
not elicit immune responses. A sharp increase in viral load subsequently occurs 
in the oral cavity and blood within 10 days of symptom onset. An early type I IFN 
response during this period is associated with a marked drop in blood pDC 
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numbers and polyclonal CD8 T cell activation, without notable symptoms. 
Symptom onset coincides with a developing adaptive immune response and a 
strong type II interferon signature. Severity of illness correlates most strongly with 
increased CD8 T cell numbers, confirming the notion of infectious mononucleosis 
as an immunopathologic disease. The sharply increased viral loads that are 
presumed to drive an exuberant T cell response are already underway prior to 
symptom onset, providing a potential explanation for the lack of a clear-cut 
benefit from antiviral drugs in infectious mononucleosis (230). We also speculate 
that pre-existing adaptive immunity to EBV would change the dynamics of 
infection in the oral cavity and thereby prevent IM in adolescents and adults. 
 
Materials and Methods 
Study design 
Samples analyzed here were obtained from two studies: one with a large number 
of subjects and less frequent sampling (Mono 5) (14) and another with a smaller 
number of subjects with more frequent sampling (Class of 2016). For the Mono 5 
study, healthy undergraduate volunteers from the University of Minnesota were 
recruited in 2006 and 2007. We screened 546 participants for IgG antibodies 
against EBV viral capsid antigen (EBV VCA IgG) and EBV nuclear antigen-1 
(EBNA-1). Of the 202 eligible EBV-naïve subjects, 143 (71%) were enrolled in 
the prospective study. Blood and oral washings were collected approximately 
every 4-8 weeks from enrolled participants during the academic year. Symptoms 
between visits were reported via an electronic monitoring journal. Subjects with 
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symptoms consistent with acute primary EBV infection were asked for an 
additional visit which included a physical exam, laboratory-confirmation of 
primary EBV infection via heterophile, EBV-specific serology, and viral titer in the 
oral cavity or blood. Primary EBV infection was defined as a positive EBV 
antibody test and the presence of EBV DNA in the blood and/or oral cavity of a 
subject who was previously negative for both EBV antibodies and EBV DNA. All 
participants were monitored with follow-up visits. The Class of 2016 study was 
similar to the above except blood and/or oral washings were collected 
approximately every 2 weeks. We screened 279 participants and 87 EBV-naïve 
subjects were enrolled in 2012, 16 of whom experienced primary EBV infection 
during their 9 month freshman year.  
 
Ethics Statement 
All participants gave written informed consent and the University of Minnesota 
Institutional Review Board approved all protocols used. 
 
Samples collection and handling 
Subjects gave oral wash samples by gargling with 22mL of normal saline. 
Peripheral blood was obtained via venipuncture into EDTA Vacutainer® tubes 
(Fisher Scientific). Blood Peripheral blood mononuclear cells (PBMCs) were 
isolated by Accuspin™ System-Histopaque®-1077 (Sigma-Aldrich) density 
gradient centrifugation per manufacturer’s instructions. PBMC were divided into 
1x10^7 cells/mL aliquots in a 90% FBS and 10% dimethylsulfoxide solution to 
108 
prevent cell damage (Sigma-Aldrich). Vials were placed inside Mr. Frosty 
freezing containers (Thermo Scientific) and frozen at -80°C per the 
manufacturer’s instructions, then transferred to liquid nitrogen for long term 
storage. Cells were rapidly thawed in a 37°C water bath, diluted to 10ml in RPNK 
media supplemented with 50U/ml benzonase (Novagen) (RPNK media: RPMI 
1640 (Cellgro) supplemented with 10% FBS (Atlanta Biologicals), 2% Penicillin - 
Streptomycin (5000U/ml, 5000µg/ml respectively, GIBCO, Invitrogen) and 1% L-
glutamine (29.2mg/ml, GIBCO)). Cells were then counted using a 
hemocytometer and divided into separate fractions for flow cytometry, RNA 
processing, and/or DNA processing. 
 
Flow cytometry staining and analysis 
Multiple time points were chosen from subjects who gave a blood sample during 
the incubation period. 1 to 2 x10^6 PBMCs from each of these time points were 
used in each stain. The following antibodies were used to identify relevant 
surface and intracellular markers: CD3 (UCHT1), CD4 (RPA-T4), CD11a (HI111), 
CD20 (2H7), CD123 (6H6), PD-1 (MIH4), CD25 (BC96), Foxp3 (PCH101) 
(eBioscience); CD45RA (HI100), CD38 (HIT2), CD16 (3G8), CD57 (HCD57), 
CD14 (M5E2), CD19 (HIB19), BDCA-2 (201A) (BioLegend); CD56 (NCAM16.2), 
HLA-DR (G46-6), CD11c (B-ly6) (Becton Dickinson); NKG2A (Z199), 
KIR2DL1/2DS1 (EB6B), KIR2DL2/2DL3/2DS2 (GL183) (Beckman Coulter); CD8 
(3B5) (Invitrogen); KIR3DL1 (DX9), KIR3DL2 (539304) (R&D systems). 
Intracellular granzyme B staining was performed using the Cytofix/Cytoperm kit 
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per the manufacturer’s instructions (BD). Intranuclear Foxp3 staining was 
performed using the Foxp3 / Transcription Factor Staining Buffer Set per the 
manufacturer’s instructions (eBioscience). All samples were acquired using an 
LSR II (BD) and analyzed with FlowJo software (TreeStar).  
 
RNA and DNA extraction 
For each sample, 1-2 x 106 PMBCs were used for each RNA extraction. Cells 
were first homogenized using QIAshredder columns (Qiagen) per the 
manufacturer’s instructions. RNA was then extracted using RNeasy kit (Qiagen) 
with on-column DNase step (Qiagen) per the manufacturer’s instructions. RNA 
was then quantified using a Nanodrop 2000/2000c spectrophotometer (Thermo 
Scientific) and kept frozen at -80°C. DNA extractions were performed with the 
Qiagen QIAmp Blood Mini kit per the manufacture’s instructions, using either 200 
µL of whole blood or 5x10^6 PBMC. 
 
Peptide MHC class I tetramers reagents 
An EBV BMLF1259–267 (GLCTLVAML)-A*0201 tetramer reagent was 
purchased from ProImmun. Other biotinylated MHC-peptide monomers were 
obtained from the National Institutes of Health (NIH) tetramer facility: EBV 
BRLF1109–117 (YVLDHLIVV)-A*0201, EBV BRLF1147–155 (RVRAYTYSK)-
A*03, EBV BZLF1190–197 (RAKFKQLL)-B*08, EBV EBNA3A325–333 
(FLRGRAYGL)-B*08, EBNA3A379–387 (RPPIFIRRL)-B*07, and EBNA3A603–
611 (RLRAEAQVK)-A*03. Before use, APC-streptavidin (Invitrogen) was added 
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to monomers at a 4:1 molar ratio overnight in the dark at 4°C to generate 
fluorescent pMHCI tetramer complexes. All tetramers were stored in the dark at 
4°C. 
 
cDNA synthesis 
cDNA was generated with 100ng of starting RNA using the SuperScript III 
Platinum Two-Step qRT-PCR Kit (Invitrogen) per the manufacturer’s instructions. 
Samples were stored at -20°C. 
 
Quantitative PCR  
Standard quantitative PCR was performed with FastStart Universal SYBR Green 
Master (Rox) (Roche) per the manufacture’s instructions. Additional data were 
generated with precoated “SuperArray” PCR plates. 43 genes were selected for 
analysis by PCR from a larger list of changed genes in IM subjects and other 
acute viral infections that comprised relevant functional groupings as assessed 
by Ingenuity Pathway Analysis as previously described (87). 384-well SuperArray 
plates pre-coated with primers for the desired 43 genes plus 5 controls were 
obtained as a custom order from SABiosciences. 10 µL of cDNA per subject was 
used with RT2 Real-time SYBR green/Rox PCR master mix (SABiosciences) for 
qRT-PCR analysis. Products were detected using an ABI Prism 7900HT 
Sequence Detection System (Applied Biosystems). The genes ACTB, B2M, and 
RPL13A were used as housekeeping genes during the calculation of fold 
changes. Fold changes were calculated as: 2^(Δ Acute Housekeeping Control – 
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Baseline Housekeeping Control)/2^(Δ Acute Gene of Interest – Baseline Gene of 
Interest).  
 
Heatmap generation 
Fold change values obtained by quantitative PCR were imported into the open 
source program Cluster 3.0, (228) which clustered the genes hierarchically using 
a Pearson non-averaged correlation and average linkage. Heatmaps were then 
visualized using the program Java Treeview. (229) 
 
Nested PCR 
PCR was performed with the HotStarTaq master mix kit (Qiagen) per the 
manufacture’s instructions. Primers specific for EBNA1 (249) were used (outer-F 
5’-GTA GAA GGC CAT TTT TCC AC-3’; outer-R 5’-CTC CAT CGT CAA AGC 
TGC A-3’; inner-F 5’-AGA TGA CCC AGG AGA AGG CCC AAG C-3’; inner-R 5’-
CAA AGG GGA GAC GAC TCA ATG GTG T-5’).  
 
 
 
 
 
 
 
 
112 
 
 
 
 
Chapter 4 
Discussion 
 
113 
DISCUSSION 
 Most infected individuals carry EBV for life without significant disease, and 
yet EBV continues to be a significant human pathogen. Despite over fifty years of 
EBV related research it is still unclear why some people experience infectious 
mononucleosis and why a small portion of the infected population progress to 
EBV related sequelae. Many unknowns remain regarding the progression of 
primary EBV infection, particularly in regard to how immunologic controls 
influence outcomes during the acute and chronic phases of infection. While our 
analysis has largely been limited to the acute phase of infection, examination of 
events surrounding primary infection may inform important aspects of future 
treatment regimens or vaccine formulations. 
 Specifically, our results seem to support the notion that infectious 
mononucleosis in an immunopathologic disease, and is not directly driven by 
EBV. This stance remains somewhat controversial given previous work from our 
group (14) and one other study which examined severity of illness (15). A 
correlation was observed between high viral loads and severity of illness in these 
studies, though whether or not viremia is truly driving disease or is merely a 
passenger or mechanistically unrelated. A stronger correlation was observed 
between CD8 T cell numbers and severity of illness in the study where cell 
phenotyping was performed (14). Evidence from individuals with asymptomatic 
seroconversion (71) correlates more closely with the data collected in the studies 
summarized in this thesis. Taken together, we propose that high viral loads are 
not necessarily indicative of symptomatic illness, and that overexpansion of CD8 
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T cells is more likely to cause infectious mononucleosis. This is consistent with 
our gene expression profiling studies which found a higher similarity between 
infectious mononucleosis and hemophagocytic diseases than between infectious 
mononucleosis acute viral infections (87). Furthermore, EBV is known to cause 
severe immunopathologic complications in certain cases (84, 134). This may 
provide an explanation as to why antiviral drugs have comparatively little efficacy 
during infectious mononucleosis as compared with other acute herpesvirus 
reactivations. 
 As an adjunct to these considerations, viral infection of peripheral B cells 
in the periphery and those in the oropharynx appear to be controlled 
independently. We observed a disconnect between viral dissemination from the 
oral cavity and viral shedding in the saliva. Our data do not adequately explain 
why viral shedding in the oral cavity should happen so suddenly after presumably 
being present in tonsillar tissues for several weeks. In many individuals in our 
study, large-scale replication of EBV in the oral cavity (likely in squamous 
epithelial cells given the envelope glycoprotein content of salivary EBV) was 
observed after high sensitivity detection of virus in the blood. While a larger 
number of oral cells would likely surmount this sensitivity issue, the rapidly 
increasing number of copies of EBV is still inconsistent with even an exponential 
mode of replication. Thus, some other control is in place to limit viral replication in 
the oral cavity during primary infection. 
 It seems probable that this control is mediated by either innate immune 
mechanisms local to the oropharynx, specifically through type I IFN, or by factors 
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intrinsic to the virus itself. CD8 T cell infiltration into the tonsil remains relatively 
poor, even during the acute phase of infectious mononucleosis when EBV 
specific CD8 T cells make up a large proportion of circulating lymphocytes (250). 
Furthermore, T cells that do infiltrate tend to be specific for latent rather than lytic 
antigens (250). NK cells are unlikely to be involved during the incubation period 
as they preferentially target only lytically infected cells (113). No EBV specific 
response is detectable until the onset of symptoms, either in terms of expansion 
or activation. These findings support a model in which oral cells may be only 
rarely infected, and the largest reservoir of virus in the oral cavity may be 
transformed B cells. These Latency III cells replicate as lymphoblastoid cells for 
the first several weeks, simultaneously “vertically” replicating the EBV episome. 
Some triggering reactivation event precipitates a switch from Latency III to lytic 
infection, allowing for infection of epithelial cells by newly budded B cell derived 
virus. 
 Controlling early infection in epithelial cells may therefore not be of 
tremendous import when formulating an effective prophylactic vaccine. Indeed, 
what is the goal of an effective vaccine? Complete prevention of viral latency 
through sterilizing immunity has long been the gold standard objective of most 
prophylactic vaccines, especially for other oncogenic viruses such as hepatitis 
and human papilloma virus. Previous work on the development of vaccines for 
HHVs however, has shown that it may not be necessary for preventing disease. 
The vaccine for varicella zoster virus has been considered successful although it 
does not provide sterilizing immunity against infection with wild-type virus (251). 
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Given hypotheses regarding high viral titres being related to EBV related disease, 
simply reducing the viral setpoint may be sufficient to abrogate future sequelae 
and complications. 
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Gene 
Symbol Common and/or Official Name 
Fold 
Change 
IFI27 interferon, alpha-inducible protein 27 10.416 
TYMS TS or thymidylate synthetase 8.973 
KIAA0101 PAF, PAF15, p15PAF, or p15(PAF) 8.162 
CDC20 cell division cycle 20 homolog 7.391 
CDCA7 JPO1 or cell division cycle associated 7 6.864 
TOP2A topoisomerase (DNA) II alpha 6.692 
ANKRD22 ankyrin repeat domain 22 6.680 
CCNB2 cyclin B2 6.644 
MELK maternal embryonic leucine zipper kinase 6.491 
CCNA2 cyclin A2 6.451 
GINS2 GINS complex subunit 2 6.413 
GBP1 guanylate binding protein 1, interferon-inducible 6.396 
CDC45L cell division cycle 45 homolog 6.373 
CDCA5 SORORIN or cell division cycle associated 5 6.267 
LAG3 lymphocyte-activation gene 3 6.069 
MT1E metallothionein 1E 6.049 
IFNG interferon, gamma 5.876 
UBE2C ubiquitin-conjugating enzyme E2C 5.794 
TK1 thymidine kinase 1, soluble 5.669 
KIFC1 kinesin family member C1 5.554 
BIRC5 baculoviral IAP repeat containing 5 5.553 
MCM4 minichromosome maintenance complex component 4 5.537 
CEP55 centrosomal protein 55kDa 5.532 
GBP5 guanylate binding protein 5 5.441 
CDT1 chromatin licensing and DNA replication factor 1 5.278 
AURKB aurora kinase B 5.263 
CDC2 CDK1 or cyclin-dependent kinase 1 5.246 
MCM2 minichromosome maintenance complex component 2 5.225 
CDKN3 cyclin-dependent kinase inhibitor 3 or KAP1 5.170 
DLG7 HURP or DLGAP5 5.162 
HMMR RHAMM or hyaluronan-mediated motility receptor 5.047 
ACOT7 BACH or acyl-CoA thioesterase 7 5.018 
NCAPG non-SMC condensin I complex, subunit G 4.972 
NUSAP1 nucleolar and spindle associated protein 1 4.965 
CHEK1 checkpoint kinase 1 or CHK1 4.819 
MCM10 minichromosome maintenance complex component 10 4.812 
OIP5 LINT-25 4.774 
CENPM centromere protein M 4.772 
TIMD4 TIM4 or T-cell immunoglobulin and mucin domain containing 4 4.765 
PTTG1 pituitary tumor-transforming 1 4.720 
KIF11 EG5 4.661 
ASPM asp (abnormal spindle) homolog, microcephaly 4.653 
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associated 
KIF20A MKLP2 4.584 
CXCL10 IP-10 4.529 
PTTG3 PTTG3P or pituitary tumor-transforming 3, pseudogene 4.434 
STMN1 stathmin 1 4.222 
FEN1 flap structure-specific endonuclease 1 4.196 
POLE2 polymerase (DNA directed), epsilon 2, accessory subunit 4.169 
TRIP13 thyroid hormone receptor interactor 13 4.130 
TTK MPS1 4.075 
STAT1 signal transducer and activator of transcription 1 4.036 
CENPN centromere protein N 3.982 
OASL 2'-5'-oligoadenylate synthetase-like 3.975 
TPX2 microtubule-associated, homolog 3.975 
CENPA centromere protein A 3.963 
GMNN geminin, DNA replication inhibitor 3.918 
PLK4 polo-like kinase 4 or SAK 3.909 
SLC27A2 solute carrier family 27 (fatty acid transporter), member 2 3.862 
POLQ polymerase (DNA directed), theta 3.840 
CKAP2L cytoskeleton associated protein 2-like 3.833 
TUBA1C tubulin, alpha 1c 3.825 
CD38 CD38 molecule 3.823 
MT2A metallothionein 2A 3.823 
EXO1 exonuclease 1 3.814 
RAD51AP1 RAD51 associated protein 1 3.807 
GBP4 guanylate binding protein 4 3.796 
BUB1 budding uninhibited by benzimidazoles 1 3.754 
STIL SCL/TAL1 interrupting locus or SIL 3.721 
PCNA proliferating cell nuclear antigen 3.675 
HJURP Holliday junction recognition protein 3.671 
AURKA aurora A or aurora kinase A 3.669 
KIF14 kinesin family member 14 3.659 
CD8A CD8a molecule 3.632 
APOBEC3H apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3H 3.607 
MND1 meiotic nuclear divisions 1 homolog 3.602 
CDCA8 BOREALIN or cell division cycle associated 8 3.596 
CKS2 CDC28 protein kinase regulatory subunit 2 3.592 
PRC1 protein regulator of cytokinesis 1 3.574 
MCM6 minichromosome maintenance complex component 6 3.566 
CCNF cyclin F or FBX1 3.553 
SPC24 NDC80 kinetochore complex component, homolog 3.417 
E2F2 E2F transcription factor 2 3.413 
KIF15 HKLP2 3.413 
PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional peptidase 2) 3.392 
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C12orf48 PARPBP; PARI 3.391 
KIF2C MCAK 3.390 
C18orf56 chromosome 18 open reading frame 56 3.389 
GZMH granzyme H 3.318 
IDH2 isocitrate dehydrogenase 2 (NADP+), mitochondrial 3.286 
CDCA2 Repo-Man or cell division cycle associated 2 3.242 
FANCI Fanconi anemia, complementation group I 3.234 
ATAD2 ANCCA or ATPase family, AAA domain containing 2 3.232 
UBE2T ubiquitin-conjugating enzyme E2T 3.214 
C1QB complement component 1, q subcomponent, B chain 3.208 
LMNB1 lamin B1 3.168 
CDCA3 cell division cycle associated 3 3.160 
ASF1B ASF1 anti-silencing function 1 homolog B or CIA-II 3.147 
APOBEC3G apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G 3.146 
PHGDH phosphoglycerate dehydrogenase 3.141 
RFC4 replication factor C (activator 1) 4 3.111 
WDR51A POC1A or PIX2 3.107 
MT1G metallothionein 1G 3.048 
PSAT1 phosphoserine aminotransferase 1 3.040 
CHI3L2 YKL-39 or chitinase 3-like 2 3.026 
C6orf173 CENPW; CUG2; centromere protein W 2.999 
NDC80 HEC1; TID3; KNTC2 2.978 
MT1A metallothionein 1A 2.950 
C3orf14 chromosome 3 open reading frame 14 2.937 
IL32 interleukin 32 2.909 
VAMP5 vesicle-associated membrane protein 5 2.907 
MCM5 minichromosome maintenance complex component 5 2.905 
MTE MT1IP; metallothionein 1I, pseudogene 2.897 
FCGR1B Fc fragment of IgG, high affinity Ib, receptor (CD64) 2.876 
CHAF1B CAF1; chromatin assembly factor 1, subunit B (p60) 2.853 
SERPING1 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 2.844 
HELLS LSH; helicase, lymphoid-specific 2.837 
RRM1 ribonucleotide reductase M1 2.834 
RACGAP1 MgcRacGAP; Rac GTPase activating protein 1 2.814 
SCD SCD1; stearoyl-CoA desaturase (delta-9-desaturase) 2.781 
PSME2 PA28B; proteasome (prosome, macropain) activator subunit 2 (PA28 beta) 2.769 
CDC7 CDC7L1; cell division cycle 7 homolog (S. cerevisiae) 2.767 
C16orf75 RMI2, RecQ mediated genome instability 2, homolog (S. cerevisiae) 2.747 
RAD51 RAD51 homolog (S. cerevisiae) 2.747 
SMC2 CAP-E; structural maintenance of chromosomes 2 2.738 
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FHL2 four and a half LIM domains 2 2.724 
SMC4 CAP-C; structural maintenance of chromosomes 4 2.692 
LY6E RIGE; SCA2; TSA-1 2.682 
RBBP8 CTIP; SCKL2; retinoblastoma binding protein 8 2.682 
EPSTI1 BRESI1; epithelial stromal interaction 1 (breast) 2.664 
EZH2 enhancer of zeste homolog 2 (Drosophila) 2.651 
RPL29 HIP; L29; ribosomal protein L29 2.651 
HMGA1 high mobility group AT-hook 1 2.636 
CD8B CD8b molecule 2.630 
C20orf100 TOX2; TOX high mobility group box family member 2 2.628 
ENDOGL1 EXOG; endo/exonuclease (5'-3'), endonuclease G-like 2.618 
TIMELESS TIM; timeless homolog (Drosophila) 2.618 
C18orf24 SKA1; spindle and kinetochore associated complex subunit 1 2.610 
FBXO6 FBS2; F-box protein 6 2.601 
MYL6B myosin, light chain 6B, alkali, smooth muscle and non-muscle 2.588 
USP54 ubiquitin specific peptidase 54 2.587 
FLJ33590 CXXC11; CXXC finger protein 11 2.583 
PYHIN1 IFIX; pyrin and HIN domain family, member 1 2.564 
RARRES3 RIG1; TIG3; retinoic acid receptor responder (tazarotene induced) 3 2.560 
LAP3 leucine aminopeptidase 3 2.543 
TROAP TASTIN; trophinin associated protein 2.543 
GFI1 SCN2; growth factor independent 1 transcription repressor 2.540 
PSMB8 LMP7; proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional peptidase 7) 2.524 
MCM7 minichromosome maintenance complex component 7 2.522 
GCH1 GTP cyclohydrolase 1 2.521 
TUBG1 tubulin, gamma 1 2.516 
GALM galactose mutarotase (aldose 1-epimerase) 2.500 
DONSON CIITA; downstream neighbor of SON 2.487 
MTHFD2 
methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 2, methenyltetrahydrofolate 
cyclohydrolase 
2.487 
MLF1IP CENPU; MLF1 interacting protein 2.486 
C17orf53 chromosome 17 open reading frame 53 2.485 
GINS3 PSF3; GINS complex subunit 3 (Psf3 homolog) 2.485 
IFI6 G1P3; interferon, alpha-inducible protein 6 2.483 
C16orf59 chromosome 16 open reading frame 59 2.480 
GBP2 guanylate binding protein 2, interferon-inducible 2.476 
NME1 NM23; NM23-H1; NME/NM23 nucleoside diphosphate kinase 1 2.464 
KLRD1 CD94; killer cell lectin-like receptor subfamily D, member 1 2.460 
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CDK2 cyclin-dependent kinase 2 2.457 
TAP1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 2.452 
PRR11 proline rich 11 2.447 
PSMA3 HC8; proteasome (prosome, macropain) subunit, alpha type, 3 2.447 
OBFC2B NABP2; SSB1; OBFC2B; nucleic acid binding protein 2 2.443 
C1orf41 HSPB11; heat shock protein family B (small), member 11 2.437 
OTOF DFNB9; DFNB6; otoferlin 2.437 
RPL39L ribosomal protein L39-like 2.436 
UBE2L6 UBCH8; ubiquitin-conjugating enzyme E2L 6 2.436 
MCM3 minichromosome maintenance complex component 3 2.433 
ADA adenosine deaminase 2.429 
CACYBP SIP; calcyclin binding protein 2.429 
C6orf190 THEMIS; thymocyte selection associated 2.428 
CKS1B CKS1; CDC28 protein kinase regulatory subunit 1B 2.427 
SLAMF8 SLAM family member 8 2.420 
FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) 2.414 
ZWILCH Zwilch, kinetochore associated, homolog (Drosophila) 2.412 
GTSE1 G-2 and S-phase expressed 1 2.409 
NUDT1 MTH1; nudix (nucleoside diphosphate linked moiety X)-type motif 1 2.408 
ZNF683 zinc finger protein 683 2.396 
PPIL5 LRR1; leucine rich repeat protein 1 2.387 
STK39 SPAK; serine threonine kinase 39 2.377 
WARS tryptophanyl-tRNA synthetase 2.376 
TFDP1 transcription factor Dp-1 2.369 
PAICS ADE2; AIRC; PAIS; ADE2H1 2.362 
ANLN anillin, actin binding protein 2.359 
DUT dUTPase; deoxyuridine triphosphatase 2.356 
PDCD1 PD-1; programmed cell death 1 2.344 
C6orf129 CCDC167; coiled-coil domain containing 167 2.343 
PRF1 perforin 1 (pore forming protein) 2.335 
CASP7 caspase 7, apoptosis-related cysteine peptidase 2.330 
IFI16 PYHIN2; interferon, gamma-inducible protein 16 2.324 
CCNE1 cyclin E1 2.323 
PSMB2 proteasome (prosome, macropain) subunit, beta type, 2 2.323 
CCDC28B coiled-coil domain containing 28B 2.318 
FGFBP2 fibroblast growth factor binding protein 2 2.313 
HMGB2 high mobility group box 2 2.313 
BRCA1 breast cancer 1, early onset 2.308 
GCUD2 FAM72D; family with sequence similarity 72, member D 2.299 
TIPIN TIMELESS interacting protein 2.293 
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C16orf33 SNRNP25; small nuclear ribonucleoprotein 25kDa (U11/U12) 2.287 
WDR34 WD repeat domain 34 2.287 
TUBB tubulin, beta class I 2.286 
RTP4 IFRG28; receptor (chemosensory) transporter protein 4 2.275 
SLAMF7 CS1; CD319; CRACC 2.273 
MCOLN2 TRPML2; mucolipin 2 2.266 
CCDC99 SPDL1; spindle apparatus coiled-coil protein 1 2.262 
CCDC34 coiled-coil domain containing 34 2.261 
FCRL6 Fc receptor-like 6 2.261 
PARP9 BAL1; poly (ADP-ribose) polymerase family, member 9 2.260 
RFC5 RFC36; replication factor C (activator 1) 5, 36.5kDa 2.259 
PSMG1 PAC1; DSCR2; proteasome (prosome, macropain) assembly chaperone 1 2.252 
C1orf135 AUNIP; AIBP; aurora kinase A and ninein interacting protein 2.251 
APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B 2.249 
ORC1L ORC1; PARC1; origin recognition complex, subunit 1 2.247 
PHF19 PCL3; PHD finger protein 19 2.247 
C9orf140 SAPCD2; suppressor APC domain containing 2 2.243 
CENPL centromere protein L 2.239 
NUF2 CDCA1; NUF2, NDC80 kinetochore complex component, homolog (S. cerevisiae) 2.232 
IL28RA interleukin 28 receptor, alpha (interferon, lambda receptor) 2.222 
PXMP2 PMP22; peroxisomal membrane protein 2, 22kDa 2.218 
RANBP1 RAN binding protein 1 2.218 
FASLG FASL; CD178; CD95L; TNFSF6 2.216 
EBP emopamil binding protein 2.210 
PGAM1 phosphoglycerate mutase 1 (brain) 2.209 
ALS2CR4 TMEM237 2.206 
TAP2 transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 2.205 
MRPL10 mitochondrial ribosomal protein L10 2.200 
SH2D1A LYP; SAP; XLP; SH2 domain containing 1A 2.199 
IFIT3 IFIT4; RIG-G; interferon-induced protein with tetratricopeptide repeats 3 2.197 
ARPC5L ctin related protein 2/3 complex, subunit 5-like 2.196 
TIPRL TIP41, TOR signaling pathway regulator-like (S. cerevisiae) 2.194 
POLA2 polymerase (DNA directed), alpha 2, accessory subunit 2.187 
UNG UNG1; UNG2; uracil-DNA glycosylase 2.186 
LGALS3BP MAC-2-BP; G3BP; lectin, galactoside-binding, soluble, 3 binding protein 2.184 
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RPA3 replication protein A3, 14kDa 2.177 
SNRPA U1A; small nuclear ribonucleoprotein polypeptide A 2.177 
BAK1 BAK; BCL2-antagonist/killer 1 2.176 
APOL3 apolipoprotein L, 3 2.173 
TCTEX1D2 Tctex1 domain containing 2 2.173 
NCAPD2 CNAP1; non-SMC condensin I complex, subunit D2 2.168 
GZMB granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) 2.167 
APITD1 MHF1; CENPS 2.165 
RPS7 S7; ribosomal protein S7 2.165 
FAM33A SKA2; spindle and kinetochore associated complex subunit 2 2.164 
AGK MULK; acylglycerol kinase 2.156 
PTPLAD1 B-IND1; protein tyrosine phosphatase-like A domain containing 1 2.154 
MRPL12 mitochondrial ribosomal protein L12 2.153 
NUP37 nucleoporin 37kDa 2.153 
PRIM1 primase, DNA, polypeptide 1 (49kDa) 2.145 
DNAJC9 DnaJ (Hsp40) homolog, subfamily C, member 9 2.134 
CENPK centromere protein K 2.131 
MTHFD1 
methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1, methenyltetrahydrofolate 
cyclohydrolase, formyltetrahydrofolate synthetase 
2.131 
KIF19 kinesin family member 19 2.129 
CXCR3 MigR; IP10-R; chemokine (C-X-C motif) receptor 3 2.128 
RAB33A RabS10; RAB33A, member RAS oncogene family 2.124 
FANCG Fanconi anemia, complementation group G 2.123 
GZMA granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) 2.122 
CXCL9 MIG; chemokine (C-X-C motif) ligand 9 2.120 
ISG15 ISG15 ubiquitin-like modifier 2.115 
XTP3TPA DCTPP1; DCTPP1 dCTP pyrophosphatase 1 2.115 
MT1X metallothionein 1X 2.111 
PIF1 PIF1 5'-to-3' DNA helicase homolog (S. cerevisiae) 2.109 
CDC42 cell division cycle 42 (GTP binding protein, 25kDa) 2.107 
SAMD3 sterile alpha motif domain containing 3 2.102 
TRMT5 TRM5; tRNA methyltransferase 5 homolog (S. cerevisiae) 2.101 
KEAP1 kelch-like ECH-associated protein 1 2.099 
PTPN7 HEPTP; protein tyrosine phosphatase, non-receptor type 7 2.099 
HMGN2 high mobility group nucleosomal binding domain 2 2.087 
GART 
phosphoribosylglycinamide formyltransferase, 
phosphoribosylglycinamide synthetase, 
phosphoribosylaminoimidazole synthetase 
2.082 
PAQR4 progestin and adipoQ receptor family member IV 2.078 
PSMA5 PSC5; proteasome (prosome, macropain) subunit, alpha type, 5 2.078 
RALY RNA binding protein, autoantigenic (hnRNP- 2.078 
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associated with lethal yellow homolog (mouse)) 
RAD54L hRAD54; RAD54-like (S. cerevisiae) 2.077 
TGFBR3 betaglycan; transforming growth factor, beta receptor III 2.076 
SLBP stem-loop binding protein 2.071 
KCNK10 TREK-2; potassium channel, subfamily K, member 10 2.070 
MTHFD1L methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like 2.065 
RFC3 RFC38; replication factor C (activator 1) 3, 38kDa 2.065 
MSH6 mutS homolog 6 (E. coli) 2.063 
LIMA1 EPLIN; LIM domain and actin binding 1 2.062 
UCK2 UK; uridine-cytidine kinase 2 2.059 
GINS4 GINS complex subunit 4 (Sld5 homolog) 2.058 
DDX39 URH49; DEAD (Asp-Glu-Ala-Asp) box polypeptide 39A 2.056 
EXOSC3 exosome component 3 2.056 
C1orf112 chromosome 1 open reading frame 112 2.047 
POLA1 polymerase (DNA directed), alpha 1, catalytic subunit 2.044 
SPON2 spondin 2, extracellular matrix protein 2.044 
CASP3 caspase 3, apoptosis-related cysteine peptidase 2.043 
MT1F metallothionein 1F 2.040 
DPP3 DPPIII; dipeptidyl-peptidase 3 2.039 
CBX5 HP1; HP1A; chromobox homolog 5 2.038 
FBXO5 F-box protein 5 2.036 
TXNL2 GLRX3; PICOT 2.036 
BLM Bloom syndrome, RecQ helicase-like 2.034 
INCENP inner centromere protein antigens 135/155kDa 2.034 
DCLRE1A SNM1; SNM1A; DNA cross-link repair 1A 2.031 
IFI35 IFP35; interferon-induced protein 35 2.031 
CTPS CTPS1; CTP synthase 1 2.030 
DSN1 KNL3; MIS13; DSN1, MIND kinetochore complex component, homolog (S. cerevisiae) 2.030 
MRPL22 mitochondrial ribosomal protein L22 2.026 
PPP1CA PP-1A; protein phosphatase 1, catalytic subunit, alpha isozyme 2.022 
CDC123 cell division cycle 123 homolog (S. cerevisiae) 2.019 
VDAC1 voltage-dependent anion channel 1 2.018 
PSMA4 HC9; PSC9; proteasome (prosome, macropain) subunit, alpha type, 4 2.015 
C7orf24 GGCT; CRF21; gamma-glutamylcyclotransferase 2.009 
KNTC1 ROD; kinetochore associated 1 2.009 
EIF2B2 eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa 2.008 
MRPL39 mitochondrial ribosomal protein L39 2.008 
SIRPG signal-regulatory protein gamma 2.008 
TUBB2C tubulin, beta 4B class IVb 2.008 
TMEM97 MAC30; transmembrane protein 97 2.007 
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ACTL6A BAF53A; actin-like 6A 2.006 
SUV39H1 suppressor of variegation 3-9 homolog 1 (Drosophila) 2.006 
BATF basic leucine zipper transcription factor, ATF-like 2.004 
MIB2 mindbomb E3 ubiquitin protein ligase 2 2.003 
GPR56 G protein-coupled receptor 56 2.000 
TPPP3 tubulin polymerization-promoting protein family member 3 -2.000 
SWAP70 SWAP switching B-cell complex 70kDa subunit -2.001 
PLCB1 phospholipase C, beta 1 (phosphoinositide-specific) -2.003 
RNF130 GOLIATH; ring finger protein 130 -2.013 
CD300LB CLM7; TREM5; IREM3 -2.015 
TLR10 toll-like receptor 10 -2.016 
LAMC1 laminin, gamma 1 (formerly LAMB2) -2.020 
FCAR CD89; Fc fragment of IgA, receptor for -2.021 
VCAN versican -2.021 
LRP3 low density lipoprotein receptor-related protein 3 -2.026 
AFF3 LAF4; AF4/FMR2 family, member 3 -2.029 
TNFRSF4 OX40; CD134 -2.034 
ZNF395 PBF; HDBP2 -2.036 
CFD DF; FD; complement factor D (adipsin) -2.042 
GNG7 guanine nucleotide binding protein (G protein), gamma 7 -2.043 
RAB31 Rab22B; RAB31, member RAS oncogene family -2.043 
MEF2C myocyte enhancer factor 2C -2.044 
VWF von Willebrand factor -2.048 
CBX7 chromobox homolog 7 -2.056 
GALNAC4S-
6ST 
CHST15; BRAG; carbohydrate (N-
acetylgalactosamine 4-sulfate 6-O) sulfotransferase 
15 
-2.057 
S100A12 ENRAGE; S100 calcium binding protein A12 -2.059 
TSPAN9 tetraspanin 9 -2.061 
TCEA3 TFIIS; transcription elongation factor A (SII), 3 -2.065 
RASD1 AGS1; DEXRAS1; RAS, dexamethasone-induced 1 -2.068 
MPL TPOR; myeloproliferative leukemia virus oncogene -2.074 
PROK2 BV8; prokineticin 2 -2.077 
GPR162 G protein-coupled receptor 162 -2.079 
CCR7 chemokine (C-C motif) receptor 7 -2.080 
SSBP2 single-stranded DNA binding protein 2 -2.081 
TRIB1 tribbles homolog 1 (Drosophila) -2.084 
ZFHX3 ATBF1; zinc finger homeobox 3 -2.089 
CD79B IGB; CD79b molecule, immunoglobulin-associated beta -2.093 
BLK B lymphoid tyrosine kinase -2.095 
SLC26A11 solute carrier family 26, member 11 -2.095 
DENND2D DENN/MADD domain containing 2D -2.096 
PTCRA pre T-cell antigen receptor alpha -2.098 
ANG angiogenin, ribonuclease, RNase A family, 5 -2.106 
CXCL16 SRPSOX; chemokine (C-X-C motif) ligand 16 -2.110 
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SPINT2 HAI-2; serine peptidase inhibitor, Kunitz type, 2 -2.112 
DAB2 disabled homolog 2 -2.121 
NUAK2 SNARK; NUAK family, SNF1-like kinase, 2 -2.123 
ITGB5 integrin, beta 5 -2.124 
TCEAL3 transcription elongation factor A (SII)-like 3 -2.127 
MOSC1 MARC1; mitochondrial amidoxime reducing component 1 -2.130 
RHOB ras homolog family member B -2.132 
LOC90925 IGHV5-78; immunoglobulin heavy variable 5-78 (pseudogene) -2.134 
LRRC26 CAPC; leucine rich repeat containing 26 -2.136 
MGC13057 chromosome 2 open reading frame 88 -2.136 
SOCS2 suppressor of cytokine signaling 2 -2.136 
MERTK c-mer proto-oncogene tyrosine kinase -2.137 
ACTN1 actinin, alpha 1 -2.138 
DDIT4 Dig2; REDD1; DNA-damage-inducible transcript 4 -2.146 
ZNF467 EZI; zinc finger protein 467 -2.156 
D4S234E NSG1; NEEP21; neuron specific gene family member 1 -2.157 
MGST1 microsomal glutathione S-transferase 1 -2.160 
VNN3 vanin 3 -2.161 
EGR2 early growth response 2 -2.172 
FLJ43093 RAB44; RASD3; RASL13; member RAS oncogene family -2.172 
DPEP2 dipeptidase 2 -2.183 
RTN1 reticulon 1 -2.190 
SVIL supervillin -2.194 
DEF8 differentially expressed in FDCP 8 homolog (mouse) -2.196 
GPR177 EVI; MRP; GPR177 -2.196 
FCRL2 Fc receptor-like 2 -2.198 
NELL2 NEL-like 2 (chicken) -2.201 
TBC1D9 MDR1; TBC1 domain family, member 9 (with GRAM domain) -2.227 
FAM134B JK1; family with sequence similarity 134, member B -2.233 
CD163 CD163 molecule -2.236 
IL11RA interleukin 11 receptor, alpha -2.236 
CD93 C1qRP;CD93 molecule -2.247 
SPRED1 sprouty-related, EVH1 domain containing 1 -2.248 
RGS2 regulator of G-protein signaling 2, 24kDa -2.250 
PDE5A CN5A; PDE5; phosphodiesterase 5A, cGMP-specific -2.251 
TGFBI transforming growth factor, beta-induced, 68kDa -2.253 
CLEC4A DCIR; C-type lectin domain family 4, member A -2.259 
C7orf41 chromosome 7 open reading frame 41 -2.268 
MS4A6A membrane-spanning 4-domains, subfamily A, member 6A -2.273 
TPM2 tropomyosin 2 (beta) -2.273 
RBP7 CRBPIV; retinol binding protein 7, cellular -2.283 
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PTGDS PGDS; LPGDS; prostaglandin D2 synthase 21kDa (brain) -2.288 
CD19 CD19 molecule -2.290 
CXCR4 chemokine (C-X-C motif) receptor 4 -2.292 
RXRA retinoid X receptor, alpha -2.297 
BASP1 brain abundant, membrane attached signal protein 1 -2.308 
CACNA1I Cav3.3; calcium channel, voltage-dependent, T type, alpha 1I subunit -2.315 
COBLL1 COBL-like 1 -2.335 
NLRP12 NALP12; NLR family, pyrin domain containing 12 -2.336 
TSPAN18 tetraspanin 18 -2.343 
NR4A3 nuclear receptor subfamily 4, group A, member 3 -2.344 
KBTBD11 kelch repeat and BTB (POZ) domain containing 11 -2.349 
BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) -2.350 
LTB lymphotoxin beta (TNF superfamily, member 3) -2.366 
CSF3R CD114; GCSFR; colony stimulating factor 3 receptor (granulocyte) -2.367 
MAL mal, T-cell differentiation protein -2.371 
FCGBP Fc fragment of IgG binding protein -2.376 
RNASE4 ribonuclease, RNase A family, 4 -2.386 
AKR1C3 aldo-keto reductase family 1, member C3 -2.396 
LRRN3 NLRR3; leucine rich repeat neuronal 3 -2.397 
VENTX VENT homeobox -2.397 
CXCR5 chemokine (C-X-C motif) receptor 5 -2.405 
CNTNAP2 contactin associated protein-like 2 -2.417 
ZSCAN18 zinc finger and SCAN domain containing 18 -2.449 
BANK1 B-cell scaffold protein with ankyrin repeats 1 -2.451 
C5orf29 GAPT; GRB2-binding adaptor protein, transmembrane -2.496 
TCL1A TCL1; T-cell leukemia/lymphoma 1A -2.503 
CYBRD1 cytochrome b reductase 1 -2.508 
ZDHHC1 zinc finger, DHHC-type containing 1 -2.512 
BCL2 B-cell CLL/lymphoma 2 -2.513 
LY86 MD-1; lymphocyte antigen 86 -2.523 
PDK4 pyruvate dehydrogenase kinase, isozyme 4 -2.527 
OSBPL10 ORP10; OSBP9; oxysterol binding protein-like 10 -2.529 
AXIN2 axin 2 -2.543 
VIPR1 VPAC1; vasoactive intestinal peptide receptor 1 -2.550 
CHST13 C4ST3; carbohydrate (chondroitin 4) sulfotransferase 13 -2.553 
CD83 CD83 molecule -2.570 
RGS18 regulator of G-protein signaling 18 -2.572 
SLC40A1 FPN1; solute carrier family 40 (iron-regulated transporter), member 1 -2.601 
VPREB3 pre-B lymphocyte 3 -2.606 
F13A1 coagulation factor XIII, A1 polypeptide -2.651 
CD79A MB-1; IGA; CD79a molecule, immunoglobulin-associated alpha -2.713 
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FCRLA FREB; Fc receptor-like A -2.716 
PTGS1 COX1; prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) -2.721 
PPBP CXCL7; Beta-TG; NAP-2 -2.747 
SH3BGRL2 SH3 domain binding glutamic acid-rich protein like 2 -2.754 
PADI4 PAD4; peptidyl arginine deiminase, type IV -2.836 
EBI2 GPR183; G protein-coupled receptor 183 -2.850 
C5AR1 C5A; C5AR; CD88; complement component 5a receptor 1 -2.873 
THBS1 TSP1; thrombospondin 1 -2.882 
RNASE6 ribonuclease, RNase A family, k6 -2.896 
GP9 GPIX; glycoprotein IX (platelet) -2.923 
NR4A2 NURR1; nuclear receptor subfamily 4, group A, member 2 -2.954 
CD1C BDCA1; CD1c molecule -2.959 
CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta subunit 3 -3.000 
CD24 CD24 molecule -3.025 
CXCL2 MIP-2 -3.045 
G0S2 G0/G1switch 2 -3.059 
SGK serum/glucocorticoid regulated kinase 1 -3.260 
SDPR serum deprivation response -3.273 
CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 -3.480 
IRS2 insulin receptor substrate 2 -3.557 
HBEGF heparin-binding EGF-like growth factor -3.833 
OSM oncostatin M -4.324 
IER3 IEX1 or immediate early response gene 3 -4.398 
IL1B Interleukin – 1beta -4.520 
IL8 Interleukin - 8 -5.197 
PTGS2 COX2 -5.360 
 
Table A-1. Shows the complete list of 464 genes significantly up/down regulated 
during acute infection with EBV, the common and/or official name of the gene, as 
well as the average fold change within the EBV cohort. The genes shown were 
derived from analysis of EBV subjects (fold change ≥ 2 and met a statistical 
significance cutoff of p-value of ≤0.05 with Bonferonni multiple-tests correction).  
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Group Gene Symbol Common and/or Official Name 
CHI3L2 YKL-39 or chitinase 3-like 2 
CD8A CD8 
EBV 
unique GZMH granzyme H 
CD38 CD38 
LMNB1 lamin B1 
APOBEC3G apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G 
IDH2 isocitrate dehydrogenase 2 (NADP+), mitochondrial 
LAG3 lymphocyte-activation gene 3 
MT1E metallothionein 1E 
E2F2 E2F transcription factor 2 
CKS2 CDC28 protein kinase regulatory subunit 2 
ASF1B ASF1 anti-silencing function 1 homolog B or CIA-II 
ACOT7 BACH or acyl-CoA thioesterase 7 
MCM6 minichromosome maintenance complex component 6 
C18orf56 chromosome 18 open reading frame 56 
CCNB2 cyclin B2 
CDT1 chromatin licensing and DNA replication factor 1 
EXO1 exonuclease 1 
AURKB aurora kinase B 
BUB1 budding uninhibited by benzimidazoles 1 
CCNF cyclin F or FBX1 
KIFC1 kinesin family member C1 
TIMD4 TIM4 or T-cell immunoglobulin and mucin domain containing 4 
CDCA7 JPO1 or cell division cycle associated 7 
MND1 meiotic nuclear divisions 1 homolog 
SLC27A2 solute carrier family 27 (fatty acid transporter), member 2 
GINS2 GINS complex subunit 2 
KIAA0101 PAF, PAF15, p15PAF, or p15(PAF) 
TYMS TS or thymidylate synthetase 
STMN1 stathmin 1 
PCNA proliferating cell nuclear antigen 
GMNN geminin, DNA replication inhibitor 
In 
common 
with 
DENV 
ATAD2 ANCCA or ATPase family, AAA domain 
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containing 2 
CENPN centromere protein N 
CDC20 cell division cycle 20 homolog 
CDCA3 cell division cycle associated 3 
TPX2 microtubule-associated, homolog 
AURKA aurora A or aurora kinase A 
KIF14 kinesin family member 14 
HJURP Holliday junction recognition protein 
FANCI Fanconi anemia, complementation group I 
CDCA8 BOREALIN or cell division cycle associated 8 
BIRC5 baculoviral IAP repeat containing 5 
CKAP2L cytoskeleton associated protein 2-like 
CDCA2 Repo-Man or cell division cycle associated 2 
KIF2C MCAK 
POLQ polymerase (DNA directed), theta 
CDC45L cell division cycle 45 homolog 
CDCA5 SORORIN or cell division cycle associated 5 
UBE2C ubiquitin-conjugating enzyme E2C 
MCM2 minichromosome maintenance complex component 2 
TK1 thymidine kinase 1, soluble 
CCNA2 cyclin A2 
ASPM asp (abnormal spindle) homolog, microcephaly associated 
APOBEC3H apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3H 
SPC24 NDC80 kinetochore complex component, homolog 
CDC2 CDK1 or cyclin-dependent kinase 1 
HMMR RHAMM or hyaluronan-mediated motility receptor 
MCM10 minichromosome maintenance complex component 10 
OIP5 LINT-25 
C12orf48 PARPBP or PARI 
WDR51A POC1A or PIX2 
MCM4 minichromosome maintenance complex component 4 
PLK4 polo-like kinase 4 or SAK 
NUSAP1 nucleolar and spindle associated protein 1 
TOP2A topoisomerase (DNA) II alpha 
CENPA centromere protein A 
CHEK1 checkpoint kinase 1 or CHK1 
STIL SCL/TAL1 interrupting locus or SIL 
 
CENPM centromere protein M 
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CDKN3 cyclin-dependent kinase inhibitor 3 or KAP1 
NCAPG non-SMC condensin I complex, subunit G 
PTTG3 PTTG3P or pituitary tumor-transforming 3, pseudogene 
TTK MPS1 
FEN1 flap structure-specific endonuclease 1 
PTTG1 pituitary tumor-transforming 1 
MELK maternal embryonic leucine zipper kinase 
DLG7 HURP or DLGAP5 
KIF11 EG5 
KIF15 HKLP2 
CEP55 centrosomal protein 55kDa 
KIF20A MKLP2 
UBE2T ubiquitin-conjugating enzyme E2T 
POLE2 polymerase (DNA directed), epsilon 2, accessory subunit 
TRIP13 thyroid hormone receptor interactor 13 
PSAT1 phosphoserine aminotransferase 1 
PHGDH phosphoglycerate dehydrogenase 
PRC1 protein regulator of cytokinesis 1 
RAD51AP1 RAD51 associated protein 1 
RFC4 replication factor C (activator 1) 4 
IFNG interferon, gamma 
 
TUBA1C tubulin, alpha 1c 
C1QB complement component 1, q subcomponent, B chain 
IFI27 interferon, alpha-inducible protein 27 
ANKRD22 ankyrin repeat domain 22 
CXCL10 IP-10 
GBP4 guanylate binding protein 4 
GBP5 guanylate binding protein 5 
GBP1 guanylate binding protein 1, interferon-inducible 
STAT1 signal transducer and activator of transcription 1 
MT2A metallothionein 2A 
OASL 2'-5'-oligoadenylate synthetase-like 
Common 
PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 
IER3 IEX1 or immediate early response gene 3 
G0S2 G0/G1switch 2 
CXCL2 MIP-2 
IL1B interleukin – 1beta 
IL8 interleukin - 8 
Down in 
Some 
PTGS2 COX2 
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HBEGF heparin-binding EGF-like growth factor 
OSM oncostatin M 
IRS2 insulin receptor substrate 2 
SGK serum/glucocorticoid regulated kinase 1 
 
SDPR serum deprivation response 
 
Table A-2. Genes with a fold change ≥ 3. 
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Gene 
Symbol Common and/or Official Name 
ACTN1 actinin, alpha 1 
ALS2CR4 TMEM237 
ANG angiogenin, ribonuclease, RNase A family, 5 
BATF basic leucine zipper transcription factor, ATF-like 
C16ORF59 chromosome 16 open reading frame 59 
C17ORF53 chromosome 17 open reading frame 53 
C18ORF24 
SKA1; spindle and kinetochore associated complex 
subunit 1 
C18ORF56 chromosome 18 open reading frame 56 
C1ORF112 chromosome 1 open reading frame 112 
C1ORF135 AUNIP 
C9ORF140 SAPCD2 
CCNF cyclin F; FBX1 
CD300LB CD300 molecule-like family member b 
CHAF1B CAF1; chromatin assembly factor 1, subunit B (p60) 
CNTNAP2 contactin associated protein-like 2 
CXCL9 chemokine (C-X-C motif) ligand 9 
DCLRE1A SNM1; SNM1A; DNA cross-link repair 1A 
DDX39 DEAD (Asp-Glu-Ala-Asp) box polypeptide 39A 
DEF8 differentially expressed in FDCP 8 homolog 
DHRS3 dehydrogenase/reductase (SDR family) member 3 
DSN1 MIND kinetochore complex component, homolog 
ENDOGL1 
ENDOGL1; endo/exonuclease (5'-3'), endonuclease 
G-like 
FLJ33590 CXXC11 
GINS4 GINS complex subunit 4 
GP9 GPIX; glycoprotein IX 
GPR162 G protein-coupled receptor 162 
HMGN2 high mobility group nucleosomal binding domain 2 
IL32 interleukin 32 
INCENP inner centromere protein antigens 135/155kDa 
KCNK10 TREK2; potassium channel, subfamily K, member 10 
KIF19 kinesin family member 19 
LOC90925 IGHV5-78 
LRP3 low density lipoprotein receptor-related protein 3 
MCOLN2 TRPML2 
MRPL10 mitochondrial ribosomal protein L10 
NLRP12 NALP12; NLR family, pyrin domain containing 12 
OBFC2B NABP2; SSB1 
PAQR4 progestin and adipoQ receptor family member IV 
PDCD1 PD1; programmed cell death 1 
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PGAM1 phosphoglycerate mutase 1 
PIF1 PIF1 5'-to-3' DNA helicase homolog 
PPP1CA 
protein phosphatase 1, catalytic subunit, alpha 
isozyme 
PRR11 proline rich 11 
PTCRA pre T-cell antigen receptor alpha 
RALY 
RNA binding protein, autoantigenic (hnRNP-
associated with lethal yellow homolog 
SPINT2 HAI-2 
SPRED1 sprouty-related, EVH1 domain containing 1 
SSBP2 SSBP2 single-stranded DNA binding protein 2 
SVIL supervillin 
TCEAL3 transcription elongation factor A (SII)-like 3 
TLR10 toll-like receptor 10 
TNFRSF4 OX40 
TSPAN18 tetraspanin 18 
TSPAN9 tetraspanin 9 
TXNL2 PICOT; GRX3; glutaredoxin 3 
USP54 ubiquitin specific peptidase 54 
VENTX VENT homeobox 
VWF von Willebrand factor 
ZDHHC1 zinc finger, DHHC-type containing 1 
 
Table A-3. Lists genes changed during EBV infection with a fold change ≥ 2 and 
a p value of ≤ 0.05, but also had an average fold change < 1.5 in all other viral 
infections. The gene symbol and the common or official name for the gene are 
shown. 
 
